
Andrea M. Trescot, MD, Standiford Helm, MD, Hans Hansen, MD, Ramsin Benyamin, MD, Scott E. Glaser, MD, Rajive Adlaka, MD, Samir Patel, DO, and Laxmaiah Manchikanti, MD

**Background:** Opioid abuse has continued to increase at an alarming rate since our last opioid guidelines were published in 2005. Available evidence suggests a continued wide variance in the use of opioids, as documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration.

**Objectives:** The objectives of opioid guidelines by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to bring consistency in opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion.

**Design:** A broadly based policy committee of recognized experts in the field evaluated the available literature regarding opioid use in managing chronic non-cancer pain. This resulted in the formulation of the review and update of the guidelines published in 2006, a series of potential evidence linkages representing conclusions, followed by statements regarding the relationships between clinical interventions and outcomes.

**Methods:** The elements of the guideline preparation process included literature searches, literature synthesis, consensus evaluation, open forum presentations, formal endorsement by the Board of Directors of the American Society of Interventional Pain Physicians, and peer review. Based on the criteria of the U.S. Preventive Services Task Force, the quality of evidence was designated as Level I, II, and III, with 3 subcategories in Level II, with Level I described as strong and Level III as indeterminate. The recommendations were provided from 1A to 2C, varying from strong recommendation with high quality evidence to weak recommendation with low-quality or very low-quality evidence.

**Results:** After an extensive review and analysis of the literature, which included systematic reviews and all of the available literature, the evidence for the effectiveness of long-term opioids in reducing pain and improving functional status for 6 months or longer is variable. The evidence for transdermal fentanyl and sustained-release morphine is Level II-2, whereas for oxycodone the level of evidence is II-3, and the evidence for hydrocodone and methadone is Level III. There is also significant evidence of misuse and abuse of opioids.

The recommendation is 2A – weak recommendation, high-quality evidence: with benefits closely balanced with risks and burdens; with evidence derived from RCTs without important limitations or overwhelming evidence from observational studies, with the implication that with a weak recommendation, best action may differ depending on circumstances or patients’ or societal values.

**Conclusion:** Opioids are commonly prescribed for chronic non-cancer pain and may be effective for short-term pain relief. However, long-term effectiveness of 6 months or longer is variable with evidence ranging from moderate for transdermal fentanyl and sustained-re-
lease morphine with a Level II-2, to limited for oxycodone with a Level II-3, and indeterminate for hydrocodone and methadone with a Level III.

These guidelines included the evaluation of the evidence for the use of opioids in the management of chronic non-cancer pain and the recommendations for that management. These guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Because of the changing body of evidence, this document is not intended to be a “standard of care.”

**Key words:** Chronic pain, persistent pain, non-cancer pain, controlled substances, substance abuse, prescription drug abuse, dependency, opioids, prescription monitoring, drug testing, adherence monitoring, diversion

**Pain Physician 2008; 11:S5-S62**

<table>
<thead>
<tr>
<th>1.0 INTRODUCTION</th>
<th>4.4 Drug Conversions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Purpose</td>
<td>4.5 Opioid Therapy and Side Effects</td>
</tr>
<tr>
<td>1.2 Rationale and Importance</td>
<td>5.0 TERMINOLOGY OF ABUSE AND ADDICTION</td>
</tr>
<tr>
<td>1.3 Objectives and Benefits</td>
<td>5.1 Introduction</td>
</tr>
<tr>
<td>1.4 Population and Preferences</td>
<td>5.2 History</td>
</tr>
<tr>
<td>1.5 Implementation and Review</td>
<td>5.3 Terminology</td>
</tr>
<tr>
<td>1.6 Application</td>
<td>5.3.1 Substance Abuse</td>
</tr>
<tr>
<td>1.7 Focus</td>
<td>5.3.2 Substance Dependence</td>
</tr>
<tr>
<td>1.8 Methodology</td>
<td>5.3.3 Tolerance</td>
</tr>
<tr>
<td>2.0 CHRONIC PAIN</td>
<td>5.3.4 Withdrawal</td>
</tr>
<tr>
<td>2.1 Definitions</td>
<td>5.3.5 Physical Dependence</td>
</tr>
<tr>
<td>2.2 Prevalence</td>
<td>5.3.6 Addiction</td>
</tr>
<tr>
<td>2.3 Chronicity</td>
<td>5.4 Opioid Agonist Therapy</td>
</tr>
<tr>
<td>2.4 Health and Economic Impact</td>
<td>6.0 CLINICAL EFFECTIVENESS</td>
</tr>
<tr>
<td>2.5 Comorbidities</td>
<td>6.1 Introduction</td>
</tr>
<tr>
<td>3.0 OPIOIDS USE IN CHRONIC PAIN</td>
<td>6.2 Systematic Reviews</td>
</tr>
<tr>
<td>3.1 General Considerations</td>
<td>6.2.1 Effectiveness of Individual Drugs</td>
</tr>
<tr>
<td>3.2 Response to Alleged Undertreatment</td>
<td>6.3 Summary of Evidence</td>
</tr>
<tr>
<td>3.3 Prescription Opioids in Chronic Pain</td>
<td>6.4 Recommendation</td>
</tr>
<tr>
<td>3.4 Nonmedical Use of Prescription Drugs</td>
<td>7.0 ADHERENCE MONITORING</td>
</tr>
<tr>
<td>3.4.1 Physician Survey Highlights</td>
<td>7.1 Introduction</td>
</tr>
<tr>
<td>3.4.2 Pharmacist Survey Highlights</td>
<td>7.2 Screening for Opioid Abuse</td>
</tr>
<tr>
<td>3.4.3 Drug Abuse Warning Network (DAWN) Reports</td>
<td>7.3 Urine Drug Testing (UDT)</td>
</tr>
<tr>
<td>3.4.4 Healthcare and Social Costs</td>
<td>7.4 Periodic Review and Monitoring</td>
</tr>
<tr>
<td>3.5 Substance Abuse in Chronic Pain</td>
<td>7.4.1 Periodic Review</td>
</tr>
<tr>
<td>3.6 Economic Impact</td>
<td>7.4.2 Periodic Monitoring</td>
</tr>
<tr>
<td>3.7 Drug Diversion</td>
<td>7.4.3 Prescription Drug Monitoring</td>
</tr>
<tr>
<td>3.8 Controlling Diversion and Abuse</td>
<td>7.4.4 Periodic Education</td>
</tr>
<tr>
<td>3.8.1 Drug Enforcement Administration (DEA)</td>
<td>7.4.5 Pill Counts</td>
</tr>
<tr>
<td>3.8.2 State Laws and Regulations</td>
<td>8.0 PRINCIPLES OF OPIOID USAGE</td>
</tr>
<tr>
<td>3.8.3 Prescription Drug Monitoring Programs (PDMP)</td>
<td>8.1 Introduction</td>
</tr>
<tr>
<td>4.0 PHARMACOLOGICAL CONSIDERATIONS</td>
<td>8.2 Recommendation</td>
</tr>
<tr>
<td>4.1 Opioid Pharmacology</td>
<td>8.3 Basic Philosophy</td>
</tr>
<tr>
<td>4.1.1 Opioid Receptors</td>
<td>8.4 Evaluation</td>
</tr>
<tr>
<td>4.1.2 Opioid Categories</td>
<td>8.4.1 Diagnostic and Therapeutic Injections</td>
</tr>
<tr>
<td>4.1.3 Opioid Metabolism</td>
<td>8.4.2 Consultation</td>
</tr>
<tr>
<td>4.2 Adverse Effects</td>
<td>8.4.3 Informed Consent and Controlled Substance Agreement</td>
</tr>
<tr>
<td>4.3 Drug Interactions</td>
<td>9.0 DOCUMENTATION AND MEDICAL RECORDS</td>
</tr>
<tr>
<td>10.0 KEY POINTS</td>
<td></td>
</tr>
</tbody>
</table>
1.0 Introduction

1.1 Purpose
The American Society of Interventional Pain Physicians (ASIPP) has developed guidelines for the use of opioids in the management of non-cancer pain. They were last updated and published in Pain Physician journal in 2006 (1). These guidelines have been developed by ASIPP, so that physicians, lawmakers, and law enforcement agencies would better understand the role of opioids in non-cancer pain management algorithms. A better understanding of the risks and benefits of this class of medications should conceivably improve access to treatment for patients with chronic pain whose quality of life could be improved with opioids. In addition, a better understanding of the risks and benefits should also conceivably lead to a reduction in the abuse and diversion of this class of medications, consequences which are of grave importance. Many opioid proponent experts and some policy makers maintain that chronic pain remains undertreated with opioids and that the extent of the problem may have been underestimated. Similarly, some experts and many policy makers maintain that chronic pain may have been overtreated with opioids and that the extent of the problem of abuse, diversion, and deaths may have been underestimated (2-8). Regardless of these widely diverse opinions, there is incontrovertible evidence that we are in the midst of an epidemic of prescription drug abuse and this has become a public health issue as well (2-5).

1.2 Rationale and Importance
The use of opioids in the management of cancer pain and palliative care has been widely accepted. The use of opioids to treat moderate to severe acute pain is also widely accepted. The use of opioids to treat chronic non-cancer pain, however, remains controversial (6,7,9-18). The most significant consequences of long-term therapy include, but are not limited to, tolerance, physical and psychological dependence, abuse, and diversion (6,7-18). When utilized to treat cancer pain or in palliative care, the treatment objectives of pain control can typically be met, and the major concerns regarding the prolonged use of opioids do not have as much impact on therapeutic decision-making. This is also usually true when treating acute pain. These issues, however, are of grave consequence when considering the prescription of opioids for chronic benign pain with evidence of lack of effectiveness and significant complications (6-19).

Another significant factor that accounts for the discrepancy in the acceptance of the use of opioids for chronic benign pain is the actual goals of treatment in this patient population. The treatment objectives in chronic benign pain are subtly, but significantly, different and more complex than the goals of opioid therapy in the settings of terminal conditions or acute pain. The objective of the treatment of chronic pain of a non-cancer origin include, when possible, not only management of painful symptoms but an emphasis on maintaining functionality and continued participation in society. These objectives can be thwarted by the use of opioids depending on multiple factors. These factors include, but are not limited to, the psychological make up of the patient, the type of pain being treated, and the skills, knowledge, and resources of the clinician.

1.3 Objectives and Benefits
The objective of these guidelines is to provide clear and concise guidelines to physicians, to improve patient access, and avoid diversion and abuse. The perceived benefits of these guidelines include:
♦ Increased physician awareness about the current issues involving opioids and non-cancer pain
♦ Improved patient access
♦ Reduced level of opioid abuse
♦ Improved ability to manage patient expectations
♦ Reduced diversion
♦ Improved understanding by law enforcement about proper prescribing patterns
♦ Improved cooperation among patients, providers, and regulatory agencies
♦ Improved understanding by patients regarding their rights as well as their responsibilities when taking opioid medications

1.4 Population and Preferences
The population covered by these guidelines includes all patients with chronic moderate to severe pain of non-cancer origin who may be eligible for appropriate medically necessary opioid analgesic management. This management may include or be independent of interventional techniques.

1.5 Implementation and Review
The dates for implementation and review were established:
♦ Effective date – February 1, 2008
♦ Scheduled review – July 1, 2011
♦ Expiration date – January 31, 2012
1.6 Application

These guidelines were developed to be used by physicians practicing interventional pain management and do not constitute inflexible treatment recommendations. These guidelines are not intended to address all possible clinical situations where opioids might be used for non-cancer pain in clinical practice. It is expected that a provider will establish a plan of care on a case-by-case basis, taking into account an individual patient’s medical condition, personal needs, and preferences, as well as the physician’s experience. Based on an individual patient’s needs, treatment different from that outlined here could be warranted. These guidelines do not represent “standard of care.”

1.7 Focus

The focus of these guidelines is the effective management of chronic non-cancer pain, as well as the various issues involved in opioid administration. It is recognized that management of chronic non-cancer pain takes place in a wide context of healthcare, involving multiple specialists and multiple techniques. Guidelines cannot be applied to all patients. Consequently, the decision to implement a particular management approach should be based on a comprehensive assessment of the patient’s overall health status, disease state, patient preference, and physician training and skill.

1.8 Methodology

A policy committee was convened and included a broad representation of academic and clinical practitioners, representing a variety of practices and geographic areas, all recognized as experts in opioid use and management of patients with chronic non-cancer pain. This committee formalized the essentials of the guidelines. The elements of the guidelines preparation process included literature searches, literature synthesis, consensus evaluations, open forum presentations, formal endorsement by the ASIPP board of directors and peer review (20-40).

Evidence-based medicine is defined as the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients (41). It is not “cookbook” medicine, but instead requires an integration of the best external evidence combined with individual clinical expertise and the patient’s choice. While an evidence-based approach may seem to enhance the scientific rigor of guideline development, recommendations may not always meet the highest scientific standards (42). The study of pain treatments has been limited due to the subjective nature of pain, especially non-cancer pain, and the effectiveness of interventions (such as the use of opioids) has to be judged relative to non-intervention (39,43-50).

In preparation of these guidelines, it is recognized that at the core of an evidence-based approach to clinical or public health issues is, inevitably, the evidence itself, which needs to be carefully gathered and collated from a systematic literature review of the particular issues. It follow that process by which the strength of scientific evidence is evaluated in the development of evidence-based medicine recommendations and guidelines is crucial. The practice of evidence-based medicine requires the integration of individual clinical expertise with the best available clinical evidence from systematic research.

Systems for grading the strength of a body of evidence are much less uniform and consistent than those for rating study quality (24-40). Consequently, the guideline committee designed levels of evidence from Level I through Level III, adapted from the U.S. Preventive Services Task Force (USPSTF) (26) as shown in Table 1.

<table>
<thead>
<tr>
<th>I:</th>
<th>Evidence obtained from at least one properly randomized controlled trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td>II-1:</td>
<td>Evidence obtained from well-designed controlled trials without randomization.</td>
</tr>
<tr>
<td>II-2:</td>
<td>Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.</td>
</tr>
<tr>
<td>II-3:</td>
<td>Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.</td>
</tr>
<tr>
<td>III:</td>
<td>Opinions of respected authorities, based on clinical experience descriptive studies and case reports or reports of expert committees.</td>
</tr>
</tbody>
</table>

Adapted from the Agency for Healthcare Research and Quality U.S. Preventive Services Task Force (USPSTF) (Ref. 24)
Recommendations were provided based on methodological quality of supporting evidence, benefit versus risks and burdens, and implications (37) (Table 2).

2.1 Definitions

Acute pain is a vital, protective mechanism that allows us to live in an environment filled with potential dangers. On the other hand, chronic pain serves no such physiologic function, and is itself not a useful symptom. Chronic pain is difficult to define. Consequently, a combination of multiple definitions must be utilized.

- Pain that persists beyond the usual course of an acute disease or a reasonable time for any injury to heal that is associated with chronic pathologic processes that cause continuous pain or pain at intervals for months or years
- Persistent pain that is not amenable to routine pain control methods.

2.2 Prevalence

Any description of the epidemiology of chronic pain starts with its significance as a national public health problem. In a survey of chronic pain in America conducted by the American Pain Society (an advocacy group), 9% of the adult population was shown

Table 2. Grading recommendations.

<table>
<thead>
<tr>
<th>Grade of Recommendation/Description</th>
<th>Benefit vs Risk and Burdens</th>
<th>Methodological Quality of Supporting Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A/strong recommendation, high-quality evidence</td>
<td>Benefits clearly outweigh risk and burdens, or vice versa</td>
<td>RCTs without important limitations or overwhelming evidence from observational studies</td>
<td>Strong recommendation, can apply to most patients in most circumstances without reservation</td>
</tr>
<tr>
<td>1B/strong recommendation, moderate quality evidence</td>
<td>Benefits clearly outweigh risk and burdens, or vice versa</td>
<td>RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies</td>
<td>Strong recommendation, can apply to most patients in most circumstances without reservation</td>
</tr>
<tr>
<td>1C/strong recommendation, low-quality or very low-quality evidence</td>
<td>Benefits clearly outweigh risk and burdens, or vice versa</td>
<td>Observational studies or case series</td>
<td>Strong recommendation but may change when higher quality evidence becomes available</td>
</tr>
<tr>
<td>2A/weak recommendation, high-quality evidence</td>
<td>Benefits closely balanced with risks and burden</td>
<td>RCTs without important limitations or overwhelming evidence from observational studies</td>
<td>Weak recommendation, best action may differ depending on circumstances or patients’ or societal values</td>
</tr>
<tr>
<td>2B/weak recommendation, moderate-quality evidence</td>
<td>Benefits closely balanced with risks and burden</td>
<td>RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies</td>
<td>Weak recommendation, best action may differ depending on circumstances or patients’ or societal values</td>
</tr>
<tr>
<td>2C/weak recommendation, low-quality or very low-quality evidence</td>
<td>Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced</td>
<td>Observational studies or case series</td>
<td>Very weak recommendations; other alternatives may be equally reasonable</td>
</tr>
</tbody>
</table>

to suffer from moderate to severe, non-cancer-related pain (51). Further, two-thirds of these people have been living with the pain for over 5 years and the pain was found to have a significant impact on the quality of life and emotional well-being, with patients experiencing significant improvements in these factors when their pain was well controlled. Other studies have shown the prevalence of chronic pain in the adult population ranging from 2% to 40%, with a median point prevalence of 15% (52,53). Persistent pain was reported with an overall prevalence of 20% of primary care patients, with approximately 48% reporting back pain (54). A systematic review of 4 international studies conducted in developed countries found prevalence rates of any type and severity level of chronic pain ranging from 10.5% to 55.2% of the population (55). A European survey of 46,000 individuals showed that 1 in 5 people reported suffering from chronic pain (56). This survey also showed that chronic pain sufferers reported 7 years of chronic pain on average, with some reporting pain lasting more than 20 years. A survey of Americans (57) showed 9% of Americans suffer with moderate-to-severe chronic non-cancer pain. An Australian study of over 17,000 people (53) showed the prevalence of chronic pain in 17.1% of males and 20% of females with the prevalence for males peaking at 27% in the 65–69 year age group and for females, prevalence peaking at 31% in the oldest age group of 80–84 years. Further, chronic pain is not only seen in adults, but it is also seen in the elderly and children (58-63). Various non-cancer pain problems include spinal pain, osteoarthritis, ischemic pain syndromes, visceral pain syndromes, neuropathic pain syndromes, and headache.

Recent publications have confirmed the above reported findings. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States (64,65), showed more than 21% of U.S. adults, or 46.4 million persons, were found to have self-reported, physician-diagnosed arthritis. This study estimated that rheumatoid arthritis affects 1.3 million adults (down from the estimate of 2.1 million for 1995), juvenile arthritis affects 294,000 children, spondylarthritides affects from 0.6 million to 2.4 million adults, systemic lupus erythematosus affects 161,000 to 332,000 adults, systemic sclerosis affects 49,000 adults, and primary Sjögren’s syndrome affects from 0.4 million to 3.1 million adults (64). Part II of this study (65) also estimated that among U.S. adults, nearly 27 million have clinical arthritis (up from the estimate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteritis, up to 3.0 million have had self-reported gout in the past year (up from the estimate of 2.1 million for 1995), 5.0 million have fibromyalgia, 4 to 10 million have carpal tunnel syndrome, 49 million have had low back pain in the past 3 months, and 30.1 million have had neck pain in the past 3 months. These reports are considered to be the best available prevalence estimates for the United States, but for most specific conditions, more studies generalizable to the United States for addressing understudied populations are needed.

Neuropathic pain is apparently common, with an estimated prevalence in the general population of 7 to 8% (66-68). However, because neuropathic pain consists of a number of different disease-specific indications, each of which can have differing diagnostic definitions and cutoffs, it is difficult to estimate precisely its prevalence and incidence (69). Neuropathic pain also affects between 8% and 50% of all diabetics (70). Diabetic peripheral neuropathy shares certain similarities (both in clinical presentation and response to treatment) with other forms of neuropathic pain. The prevalence of neuropathic pain after thoracic surgery is high, with 57% complaining of neuropathic pain at 7–12 months, 36% at 4–5 years, and 21% at 6–7 years (71). Breast cancer patients may complain of “phantom” breast pain for months to years after surgery (72).

2.3 Chronicity

Duration of pain and its chronicity have been topics of controversy. Conventional beliefs are that most episodes of low back pain will be short-lived, with 80% to 90% of attacks resolving in about 6 weeks irrespective of the administration or type of treatment, and only 5% to 10% of patients developing persistent back pain (73-82). However, this commonly held belief has been questioned, as in reality, the condition tends to relapse, so that most patients will experience recurrent episodes. Almost 60% of spinal pain patients have suffered from chronic pain from 2 to 15 years (53,56,73-82). Further, overwhelming evidence shows that chronic persistent low back pain and neck pain in children and adults are seen in up to 60% of the patients, 5 years or longer after the initial episode (73,76-83).

2.4 Health and Economic Impact

Chronic non-cancer pain is associated with sig-
nificant economic, societal, and health impact (84-93). The cost of uncontrolled chronic pain is enormous, both to individuals and to society as it leads to a decline in the quality of life and disability. Estimates and patterns of direct healthcare expenditures among individuals with back pain in the United States reached $90.7 billion for the year 1998 (84). On average, individuals with back pain generate healthcare expenditures about 60% higher than do individuals without back pain ($3,498 per year versus $2,178). It has been estimated that the cost of healthcare for patients with chronic pain might exceed the combined cost of treating patients with coronary artery disease, cancer, and AIDS (94). In the United States, it was estimated that the cost of treatment in the first year after failed back surgery for pain was approximately $18,883 in 1997 (95). Even further, annual healthcare cost incurred by chronic pain patients, excluding cost for surgical procedures, may range from $500 to as high as $35,400, with averages ranging from $12,900 to $18,883 annually (96,97).

The economic costs for chronic pain in general have been estimated to be over $86 billion per year (97). A cross-sectional study, based on survey data from 28,902 working adults in the USA was reported in 2003 with 13% of the workforce experiencing a loss of productivity during a 2 week period due to a common pain condition (98). In monetary terms, this loss of productivity was calculated to cost $61.3 billion, with $14.4 billion due to absenteeism and the rest due to the survey participants being at work, but with impaired productivity due to the pain.

In a recent survey of expenditures and health status among adults with back and neck problems (92), self-reported back and neck problems accounted for a large proportion of health care expenditures and spine-related expenditures have increased substantially from 1997 to 2005, without evidence of corresponding improvement in self-assessed health status. In this national estimate based on annual samples of survey respondents with and without self-reported spine problems from 1997 through 2005, a total of 23,045 respondents were sampled in 1997, including 3,139 who reported spine problems. In 2005, the sample included 22,258 respondents, including 3,187 who reported spine problems. This survey showed that in 1997, the adjusted medical cost for respondents with spine problems was $4,695 (95% CI, $4,181 to $5,209), compared with $2,731 (95% CI, $2,567 to $2,904) among those without spine problems. Consequently, total estimated expenditures among respondents with spine problems increased 65% after adjusting for inflation from 1997 to 2005, more rapidly than overall health expenditures. This is in contrast to the estimated proportion of persons with back or neck problems with self-reported physical function and limitations increasing from 20.7% (95% CI, 19.9% to 21.4%) to 24.7% (95% CI, 23.7% to 25.6%) from 1997 to 2005, which is an increase of 4%.

In one study evaluating the burden and determinants of neck pain in the general population (91) and in workers (93) after evaluating numerous studies (101 for general population and 109 for workers), the 12-month prevalence of pain typically ranged between 30 and 50%, while, the 12-month prevalence of activity-limiting pain was 1.7% to 11.5% in the general population, in workers, the annual prevalence of neck pain varied from 27.1% to 47.8%, with between 11% and 14.1% of workers limiting their activities due to neck pain.

2.5 Comorbidities

Chronic pain sufferers are considered to be heavy users of healthcare services, often presenting with multiple or unexplained symptoms. Studies indicate that only 2% to 5% of chronic pain sufferers have been evaluated or treated by a pain specialist (56,99), whereas many patients seek alternative practitioners (100), and a high proportion take prescription or over-the-counter medications.

Chronic pain also has high functional impairment impact on the sufferer’s day-to-day function, with a range of activities being curtailed. Patients with chronic pain report difficulties with daily chores, social life, and work, and a higher rate of unemployment (101-104). It has been shown that 19% of patients had lost their job because of chronic pain (56). In addition, chronic pain sufferers have been shown to have low scores for quality of life (105,106).

Increased comorbidity, disability, and costs have been described widely in the chronic pain population (107-126). In a study of 1,484 community dwelling Australian women 70 to 85 years of age, daily back pain was shown to be associated with reduced quality
of life, mobility and longevity, and increased risk of coronary heart events (107). In a descriptive report of the longitudinal course of depressive symptoms and pain experienced by continuing care retirement community residents, in 169 residents, 37% met the criteria for chronic activity-limiting pain, 21% met the criteria for chronic high depressive symptoms, and 13% were comorbid (63). In another study of an elderly population, both pain and depression affected physical performance, with depression having more an influential effect on the decline of physical performance and causing increased levels of functional impairment. This was also confirmed in a prospective study of patients with disabling low back pain and depressive symptoms in a community-dwelling population of over 90,000 elderly, more than 50,000 of whom were being surveyed for the follow-up purposes after 2 years (109). This study showed that among community-dwelling elderly persons, depressive symptoms and disabling low back pain were widespread, with depressive symptoms predicting disabling low back pain and vice versa. Multiple studies have addressed the impact of chronic spinal pain (112-114), headache (115,117,118), and various types of pain.

Extensive research of involvement of psychological disorders in the chronic pain population has been published (120-134). Since pain is defined as both a physiological sensation and a psychological condition or state (126), the neural event of pain is in many ways inextricable from the psychological or phenomenological experience of pain (127). Consequently, chronic pain in particular manifests a psychological constellation of cognitive, emotional, and behavioral characteristics. Numerous studies have shown that a significant proportion of pain patients present with depression, anxiety, and somatization disorder, either alone or in combination (120-125,128-133). In studies that have evaluated chronic pain patients, the comorbidity of major depression ranged from 15% to 56%, significantly higher than the occurrence of major depression within the general population, which ranged from 5% to 10%. Similarly, the occurrence of somatization disorder ranged from 20% to 31% in chronic pain patients, compared to 1% to 4% in the general population. Consequently, the prevalence of pain is noted to increase with the association of comorbidities, and the prevalence of pain continues to increase, along with psychological and substance abuse disorders.

### 3.0 Opioids Use in Chronic Pain

#### 3.1 General Considerations

Inadequate treatment of pain has been attributed to a lack of knowledge about pain management options, inadequate understanding of addiction, or fears of investigation or sanction by federal, state, and local regulatory agencies (1-6,134-136). Proponents of opioid drug therapy for all types of pain contend that opioid analgesic therapy plays an important role in pain management and should be available when needed for the treatment of all kinds of pain, including non-cancer pain, without restriction of dosage or frequency (135). Further, the Drug Enforcement Administration (DEA) has also taken the position that clinicians should be knowledgeable about using opioids to treat pain, and should not hesitate to prescribe them when opioids are the best clinical choice of treatment (137). In addition to the DEA, model guidelines adapted by the Federation of State Medical Boards also encourage opioid management with proper documentation (138).

#### 3.2 Response to Alleged Undertreatment

The alleged undertreatment of pain as a major health problem in the United States led to the development of initiatives to address the multiple alleged barriers responsible for the undertreatment of pain. Consequently, numerous clinical guidelines have been developed, even though none of them were based on evidence-based medicine. In 2001, the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO) introduced the concept that pain was the “fifth vital sign,” in an effort to increase the awareness of pain in the hospitalized patient, and by design, improve the treatment of that pain. Unfortunately, the current emphasis on pain assessment as the fifth vital sign has resulted in the potential overmedication of a group of patients (139). The results of the effect of JCAHO regulations have been controversial (140-142). One study showed that opioid adverse drug reactions increased significantly from 11 to 24.5 per 100,000 inpatient hospital days (140). However another study (141) showed increased opioid consumption without an increase in the length of the stay, increase in the use of naloxone, or an increase in treatment for postoperative nausea and vomiting. Yet, another study (142) showed that routinely measuring pain by the fifth vital sign did not increase the quality of pain management.
Multiple reviews (6,9-19) have shown a lack of consistent effectiveness of opioids in reducing pain and improving functional status. A cost analysis of chronic spinal pain (143) suggested that treatment with medications alone did not significantly improve a patients’ ability to stand, sit, walk, travel, socialize, and work both in and outside the home. However, complementary treatment components, such as anesthetic procedures, physical therapy, group education, and cognitive-behavioral psychotherapy, seemed to directly affect patients’ pain-related functional impairments. It is argued that physicians should be encouraged to prescribe opioids because they are indispensable for the treatment of pain and suffering, because uncontrolled pain may have deleterious physical effects, and because persistent pain destroys peoples’ autonomy, dignity, and decision-making capacity (6,14,144,145). Thus, the availability of opioids has skyrocketed dramatically in the past few decades, partly due to politics and the emotional issues in part to increased sales of hydrocodone by 244% from 1997 to 2006, while methadone usage increased 1,177% and oxycodone increased 732% (Table 3 and Fig. 1) (5). Coupled with increased retail sales in therapeutic opioid usage, the pattern of type of opioid usage also has changed. In 1997, the most commonly used opioid was codeine, followed by hydrocodone and oxycodone. However, in 2006, the most commonly used opioid was oxycodone, followed by hydrocodone and morphine.

Overall, opioids increased from 50.7 million grams of medication in 1997 to 115.3 million grams of medication in 2006, an overall increase of 127% (5). In addition, the estimated number of prescriptions filled for controlled substances increased from 222 million in 1994 to 354 million in 2003 (4,171,172). Prescriptions

Table 3. Retail sales of opioid medications (grams of medication), 1997–2006.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>518,737</td>
<td>692,675 (34%)</td>
<td>964,982 (39%)</td>
<td>1,428,840* (48%)</td>
<td>1,892,691 (32%)</td>
<td>2,649,559 (40%)</td>
<td>3,683,881 (39%)</td>
<td>4,730,157 (28%)</td>
<td>5,362,815 (13%)</td>
<td>6,621,687 (23%)</td>
<td>1177%</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>4,449,562</td>
<td>6,579,719 (48%)</td>
<td>9,717,600 (48%)</td>
<td>15,305,913 (58%)</td>
<td>19,927,286 (30%)</td>
<td>22,376,892 (12%)</td>
<td>26,655,152 (19%)</td>
<td>29,177,530 (9%)</td>
<td>30,628,973 (5%)</td>
<td>37,034,220 (21%)</td>
<td>732%</td>
</tr>
<tr>
<td>Fentanyl Base</td>
<td>74,086</td>
<td>90,618 (22%)</td>
<td>107,141 (18%)</td>
<td>146,612* (37%)</td>
<td>186,083 (27%)</td>
<td>242,027 (30%)</td>
<td>317,200 (31%)</td>
<td>370,739 (17%)</td>
<td>387,928 (5%)</td>
<td>428,668 (11%)</td>
<td>479%</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>241,078</td>
<td>260,009 (8%)</td>
<td>292,506 (12%)</td>
<td>346,574* (18%)</td>
<td>400,642 (16%)</td>
<td>473,362 (18%)</td>
<td>579,372 (22%)</td>
<td>655,395 (13%)</td>
<td>781,287 (19%)</td>
<td>901,663 (15%)</td>
<td>274%</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>8,669,311</td>
<td>10,389,503 (20%)</td>
<td>12,101,621 (16%)</td>
<td>14,118,637 (17%)</td>
<td>15,594,692 (10%)</td>
<td>18,822,619 (21%)</td>
<td>22,342,174 (19%)</td>
<td>24,081,900 (8%)</td>
<td>25,803,543 (7%)</td>
<td>29,856,368 (16%)</td>
<td>244%</td>
</tr>
<tr>
<td>Morphine</td>
<td>5,922,872</td>
<td>6,408,322 (8%)</td>
<td>6,804,935 (6%)</td>
<td>7,807,511 (15%)</td>
<td>8,810,700 (13%)</td>
<td>10,264,264 (16%)</td>
<td>12,303,956 (20%)</td>
<td>14,319,243 (16%)</td>
<td>15,054,846 (5%)</td>
<td>17,507,148 (16%)</td>
<td>196%</td>
</tr>
<tr>
<td>Codeine</td>
<td>25,071,410</td>
<td>26,018,054 (4%)</td>
<td>23,917,088 (8%)</td>
<td>23,474,865* (2%)</td>
<td>23,032,641 (2%)</td>
<td>22,633,733 (2%)</td>
<td>21,865,409 (3%)</td>
<td>20,264,555 (7%)</td>
<td>18,960,038 (6%)</td>
<td>18,762,919 (1%)</td>
<td>-25%</td>
</tr>
<tr>
<td>Meperidine (Pethidine)</td>
<td>5,765,954</td>
<td>5,834,294 (1%)</td>
<td>5,539,592 (5%)</td>
<td>5,494,898* (1%)</td>
<td>5,450,204 (1%)</td>
<td>5,412,389 (1%)</td>
<td>5,239,932 (3%)</td>
<td>4,856,644 (7%)</td>
<td>4,272,520 (7%)</td>
<td>4,160,033 (-3%)</td>
<td>-28%</td>
</tr>
<tr>
<td>Total</td>
<td>30,713,010</td>
<td>56,273,194 (11%)</td>
<td>59,445,465 (6%)</td>
<td>35,962,089.84 (15%)</td>
<td>75,294,939 (11%)</td>
<td>82,874,845 (10%)</td>
<td>92,987,076 (12%)</td>
<td>98,456,163 (6%)</td>
<td>101,251,950 (6%)</td>
<td>115,272,706 (14%)</td>
<td>127%</td>
</tr>
</tbody>
</table>

Numbers in parenthesis are percentage of change from previous year. * For year 2000, data is not available; the average of 1999 and 2001 was taken. Source: www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html

for controlled substances increased by 154%, compared to the number of prescriptions written for non-controlled drugs which increased by 57% (173-175). As a result, the milligram per person use of therapeutic opioids in the United States increased from approximately 74 mg in 1997 to 329 mg per person in 2006, an increase of 347% (Table 4) (5). Fig. 2 illustrates total prescriptions for selected narcotic analgesics for 2006 (5,176,177). In 2006, there were about 35-fold more hydrocodone prescriptions, 10-fold more oxycodone prescriptions, and 2-fold more fentanyl prescriptions compared to methadone prescriptions. In addition, Americans, constituting only 4.6% of the world’s population, have been consuming 80% of the global opioid supply, and 99% of the global hydrocodone supply, along with two-thirds of the world’s illegal drugs (1-5,178-181).

Multiple authors also have evaluated the increase in opioid use along with cost and health consequences which have been increasing substantially over the years (182-184). The analysis of the National Ambulatory Medical Care Survey, using data from 1980 to 1981 and 1999 to 2000, evaluating over 130,000 visits showed the doubling of opioid use for chronic pain from 8% to 16% and for acute pain the increase was from 8% to 11% (182). In addition, the study also showed that prescriptions for more potent opioids such as hydrocodone, oxycodone, and morphine increased from 2% to 9% in visits corresponding to 5.9 million visits in 2002 — an increase of 4.6 million visits from 1980 for chronic musculoskeletal pain. Further, in the analysis of analgesic use for low back pain and its impact on health care costs and service use (183), in 2001, 55.5% of members with claims for low back services received analgesics costing a total of $1.4 million, of which 68% were opioids. Opioid use was also associated with high volume usage of low back pain services and correlated with the higher use of opioids in patients with psychogenic pain and low back pain related to orthopedic devices such as fusion. There have been reports of association of opioid use with increased disability, medical costs, subsequent surgery, and continued or late opioid use (182-186). Webster et al (185) showed that patients receiving more than 450 mg equivalent of morphine over a period of several months were, on average, disabled 69 days lon-
ger than those who received no early opioids, and also had 3 times the increased risk for surgery, along with 6 times the increased risk of receiving late opioids. Greater self-reported disability and poor function was associated with opioid use (187). Finally, an epidemiological study from Denmark (188) demonstrated worse pain, higher health care utilization, and lower activity levels in opioid treated patients compared to a matched cohort of chronic pain patients not using opioids, suggesting that when opioids are prescribed liberally, even if some patients benefit, the overall population does not. Opioids are prescribed liberally for chronic pain in Denmark. In an evaluation of primary care patients, the frequency of opioid disorders was 4 times higher in patients receiving opioid therapy compared with general population samples (3.8% vs 0.9%) (189).

3.3 Prescription Opioids in Chronic Pain

Numerous reviews have critically evaluated the effectiveness of opioid therapy in chronic pain (1,6,11-19). In a meta-analysis of opioid use in patients with chronic low back pain, Martell et al (10) concluded that opioids do not provide effective pain relief and do not increase functional status in chronic low back pain. Ballantyne (6), after directly comparing the efficacy of different opioids, concluded that a non-significant reduction in pain was present. Chou et al (11) concluded there was insufficient and poor evidence to prove the safety or effectiveness of any opioids. Kalso et al (12) in their critical analysis concluded that the mean decrease in pain intensity in most studies was only 30%, whereas only 44% of the patients continued treatment for 7 to 24 months. Furlan et al (13) provided a more somber view of opioids concluding that strong opioids were more effective with pain relief and functional outcomes, even though drop-out rates averaged 33%. Two Cochrane reviews (15,16) showed unsatisfactory long-term results in managing neuropathic (15) and nociceptive pain (16). A recent systematic review and meta-analysis (9) of efficacy and safety of long-term opioid therapy for chronic non-cancer pain concluded that many patients discontinue long-term opioid therapy due to adverse events or insufficient pain relief. However, they also concluded that weak evidence suggests that oral opioids reduce pain long-term in the relatively small proportion of individuals with chronic non-cancer pain who continue treatment. Sandoval et al (18) in a systematic review of methadone found no randomized trials for long-term use of methadone and showed only limited evidence with observational reports.

Cepeda et al (17) performed a systematic review and meta-analysis of randomized clinical trials of tramadol and concluded that tramadol is more effective than placebo for the treatment of osteoarthritis when the pain is moderate. However, tramadol was only of limited benefit when the pain was severe.

Overall, the evidence supporting the long-term analgesic efficacy is weak at best based on the present evidence. In addition, not surprisingly, epidemiological

<table>
<thead>
<tr>
<th>Type</th>
<th>1997</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>% of Change from 1997</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>22.20</td>
<td>24.01</td>
<td>24.50</td>
<td>28.11</td>
<td>31.72</td>
<td>36.95</td>
<td>44.30</td>
<td>51.55</td>
<td>54.20</td>
<td>63.03</td>
<td>184%</td>
</tr>
<tr>
<td>Methadone</td>
<td>1.94</td>
<td>2.60</td>
<td>3.47</td>
<td>5.14*</td>
<td>6.81</td>
<td>9.54</td>
<td>13.26</td>
<td>17.03</td>
<td>19.31</td>
<td>23.84</td>
<td>1,129%</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>16.68</td>
<td>24.66</td>
<td>34.99</td>
<td>55.11</td>
<td>71.75</td>
<td>80.56</td>
<td>95.97</td>
<td>105.05</td>
<td>110.27</td>
<td>133.33</td>
<td>899%</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>32.49</td>
<td>38.93</td>
<td>43.57</td>
<td>50.83</td>
<td>56.15</td>
<td>67.77</td>
<td>80.44</td>
<td>86.70</td>
<td>92.90</td>
<td>107.49</td>
<td>231%</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.28</td>
<td>0.34</td>
<td>0.39</td>
<td>0.53*</td>
<td>0.67</td>
<td>0.87</td>
<td>1.14</td>
<td>1.33</td>
<td>1.40</td>
<td>1.54</td>
<td>450%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>73.59</td>
<td>90.54</td>
<td>106.92</td>
<td>139.72</td>
<td>167.1</td>
<td>195.69</td>
<td>235.11</td>
<td>261.66</td>
<td>278</td>
<td>329.23</td>
<td>347%</td>
</tr>
</tbody>
</table>

* For year 2000 data is not available, the average of 1999 and 2001 was taken.


studies while positive with pain are less positive with regards to function and quality of life and report the failure of opioids to improve quality of life in chronic pain patients (20).

3.4 Nonmedical Use of Prescription Drugs

The National Survey on Drug Use and Health of 2006 (190) showed that an estimated 20.4 million or 8.3% of Americans, ages 12 or older were current (past month) illicit drug users. Among the illicit drugs, psychotherapeutic drugs which include prescription type pain relievers, tranquilizers, stimulants, and sedatives are included. Marijuana and hashish are the most commonly used illicit drugs with 14.8 million current users, or 6% of the U.S. population. Cocaine was used by 2.4 million, whereas hallucinogens were used in the past month by 1 million persons. However, surprisingly, next to marijuana, 7.0 million (2.8%) persons aged 12 or older had used prescription-type psychotherapeutic drugs nonmedically in the past month. Of these, 5.2 million had used pain relievers, an increase from 4.7 million in 2005 (Table 5). The categories of nonmedical use of psychotherapeutics and pain relievers were well ahead of the illicit drug use of cocaine, hallucinogens, inhalants, methamphetamine, heroin, and LSD.

The increases for current nonmedical use of psychotherapeutics over a period of the last 10 years (1997 to 2006) was 162% compared to 33% for marijuana and hashish, and 61% for cocaine. Consequently, psychotherapeutics were the only ones that showed significant increases from 2002 to 2006, whereas, marijuana and cocaine were similar over a period of 5 years (5).

Statistics of new initiatives also continue to be grim with 2.6 million persons aged 12 or older using psychotherapeutic drugs nonmedically for the first time within the past year in 2006 (190). Similarly, numbers of new users for specific psychotherapeutics in 2006 were 2.2 million for pain relievers, 1.1 million for tranquilizers, 845,000 for stimulants, and 267,000 for sedative (Table 6).

Analysis of long-term statistics based on yearly use of illicit drugs are concerning (5). The past year use of illicit drugs in 2006 was 35.77 million or 4.5% of the population, whereas nonmedical use of psychotherapeutics for the past year in the 2006 survey was 16.287
Table 5. Types of illicit drug use in the past month among persons aged 12 or older: Numbers in thousands, from 1997 to 2006.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonmedical Use of Psychotherapeutics</td>
<td>2,665</td>
<td>2,477</td>
<td>3,952</td>
<td>3,849</td>
<td>4,811</td>
<td>6,210</td>
<td>6,336</td>
<td>6,007</td>
<td>6,405</td>
<td>6,991</td>
</tr>
<tr>
<td>Pain Relievers</td>
<td>--</td>
<td>--</td>
<td>2,621</td>
<td>2,782</td>
<td>3,497</td>
<td>4,377</td>
<td>4,693</td>
<td>4,404</td>
<td>4,658</td>
<td>5,220</td>
</tr>
<tr>
<td>OxyContin*</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>325</td>
<td>334</td>
<td>276</td>
</tr>
<tr>
<td>Tranquilizers</td>
<td>845</td>
<td>655</td>
<td>1,097</td>
<td>1,000</td>
<td>1,358</td>
<td>1,804</td>
<td>1,830</td>
<td>1,616</td>
<td>1,817</td>
<td>1,766</td>
</tr>
<tr>
<td>Stimulants</td>
<td>612</td>
<td>633</td>
<td>950</td>
<td>788</td>
<td>1,018</td>
<td>1,218</td>
<td>1,191</td>
<td>1,189</td>
<td>1,067</td>
<td>1,191</td>
</tr>
<tr>
<td>Sedatives</td>
<td>187</td>
<td>210</td>
<td>229</td>
<td>175</td>
<td>306</td>
<td>436</td>
<td>294</td>
<td>265</td>
<td>272</td>
<td>385</td>
</tr>
<tr>
<td>Marijuana and Hashish</td>
<td>11,109</td>
<td>11,016</td>
<td>10,458</td>
<td>10,714</td>
<td>12,122</td>
<td>14,584</td>
<td>14,638</td>
<td>14,576</td>
<td>14,626</td>
<td>14,813</td>
</tr>
<tr>
<td>Cocaine</td>
<td>1,505</td>
<td>1,750</td>
<td>1,552</td>
<td>1,213</td>
<td>1,667</td>
<td>2,020</td>
<td>2,281</td>
<td>2,021</td>
<td>2,397</td>
<td>2,421</td>
</tr>
<tr>
<td><strong>Total Illicit Drugs</strong></td>
<td>13,904</td>
<td>13,615</td>
<td>13,829</td>
<td>14,027</td>
<td>15,910</td>
<td>19,522</td>
<td>19,470</td>
<td>19,071</td>
<td>19,720</td>
<td>20,357</td>
</tr>
</tbody>
</table>

---

- Not available.
- a Difference between estimate and 2006 estimate is statistically significant at the 0.05 level.
- b Difference between estimate and 2006 estimate is statistically significant at the 0.01 level.
- c Difference between estimate and previous year estimate is statistically significant at the 0.01 level.
- 1 Illicit drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutics used nonmedically.
- 2 Nonmedical use of prescription-type psychotherapeutics includes the nonmedical use of pain relievers, tranquilizers, stimulants, or sedatives, and does not include over-the-counter drugs.

Table 6. Past year initiates for illicit drugs from 1997 to 2006 (numbers in thousands).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Relievers(^a)</td>
<td>1,316</td>
<td>1,548</td>
<td>1,810</td>
<td>2,268</td>
<td>2,400</td>
<td>2,320</td>
<td>2,456(^b)</td>
<td>2,422(^b)</td>
<td>2,193</td>
<td>2,150</td>
<td>63%</td>
</tr>
<tr>
<td>Tranquillizers</td>
<td>668</td>
<td>860</td>
<td>916</td>
<td>1,298</td>
<td>1,212</td>
<td>1,184</td>
<td>1,071</td>
<td>1,180</td>
<td>1,286</td>
<td>1,112</td>
<td>66%</td>
</tr>
<tr>
<td>Stimulants</td>
<td>553</td>
<td>648</td>
<td>706</td>
<td>808</td>
<td>853</td>
<td>783</td>
<td>715</td>
<td>793</td>
<td>647(^a)</td>
<td>845</td>
<td>53%</td>
</tr>
<tr>
<td>Sedatives</td>
<td>120</td>
<td>147</td>
<td>164</td>
<td>191</td>
<td>225</td>
<td>209</td>
<td>194</td>
<td>240</td>
<td>247</td>
<td>267</td>
<td>123%</td>
</tr>
<tr>
<td>Marijuana</td>
<td>2,603</td>
<td>2,498</td>
<td>2,640</td>
<td>2,746</td>
<td>2,793</td>
<td>2,196</td>
<td>1,973</td>
<td>2,142</td>
<td>2,114</td>
<td>2,063</td>
<td>-21%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>861</td>
<td>868</td>
<td>917</td>
<td>1,002</td>
<td>1,140</td>
<td>1,032</td>
<td>986</td>
<td>998</td>
<td>872</td>
<td>977</td>
<td>13%</td>
</tr>
<tr>
<td>Heroin</td>
<td>114</td>
<td>140</td>
<td>121</td>
<td>114</td>
<td>114</td>
<td>147</td>
<td>115</td>
<td>92</td>
<td>118</td>
<td>108</td>
<td>91 -20%</td>
</tr>
</tbody>
</table>

Note: 2002 to 2006 data is based on 2006 National Survey on Drug Use and Health Survey Report.


Table 7. Types of illicit drug use in the past year among persons aged 12 or older from 1997 to 2006 (numbers in thousands).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonmedical Use of Psychotherapeutics(^a)</td>
<td>6,111(^h)</td>
<td>5,759(^h)</td>
<td>9,220(^h)</td>
<td>8,761(^h)</td>
<td>11,102(^h)</td>
<td>14,680(^h)</td>
<td>14,986(^h)</td>
<td>14,643(^h)</td>
<td>15,172(^h)</td>
<td>16,287(^h)</td>
<td>167%</td>
</tr>
<tr>
<td>Pain Relievers</td>
<td>--</td>
<td>--</td>
<td>6,582(^h)</td>
<td>6,466(^h)</td>
<td>8,353(^h)</td>
<td>10,992(^h)</td>
<td>11,671(^h)</td>
<td>11,256(^h)</td>
<td>11,815(^h)</td>
<td>12,649(^h)</td>
<td>NA</td>
</tr>
<tr>
<td>OxyContin(^a)</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>1,213(^h)</td>
<td>1,226(^h)</td>
<td>1,323(^h)</td>
<td>NA</td>
</tr>
<tr>
<td>Tranquillizers</td>
<td>2,122(^h)</td>
<td>1,940(^h)</td>
<td>2,728(^h)</td>
<td>2,731(^h)</td>
<td>3,673(^h)</td>
<td>4,849(^h)</td>
<td>5,051(^h)</td>
<td>5,068(^h)</td>
<td>5,249(^h)</td>
<td>5,058(^h)</td>
<td>138%</td>
</tr>
<tr>
<td>Stimulants</td>
<td>1,687(^h)</td>
<td>1,489(^h)</td>
<td>2,291(^h)</td>
<td>2,112(^h)</td>
<td>2,486(^h)</td>
<td>3,181(^h)</td>
<td>2,751(^h)</td>
<td>2,918(^h)</td>
<td>2,771(^h)</td>
<td>3,394(^h)</td>
<td>101%</td>
</tr>
<tr>
<td>Sedatives</td>
<td>638(^h)</td>
<td>522(^h)</td>
<td>631(^h)</td>
<td>611(^h)</td>
<td>806(^h)</td>
<td>981(^h)</td>
<td>831(^h)</td>
<td>737(^h)</td>
<td>750(^h)</td>
<td>926(^h)</td>
<td>45%</td>
</tr>
<tr>
<td>Marijuana and Hashish</td>
<td>19,446(^h)</td>
<td>18,710(^h)</td>
<td>19,102(^h)</td>
<td>18,589(^h)</td>
<td>21,086(^h)</td>
<td>25,755(^h)</td>
<td>25,231(^h)</td>
<td>25,451(^h)</td>
<td>25,375(^h)</td>
<td>25,378(^h)</td>
<td>31%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>4,169(^h)</td>
<td>3,811(^h)</td>
<td>3,742(^h)</td>
<td>3,328(^h)</td>
<td>4,186(^h)</td>
<td>5,902(^h)</td>
<td>5,908(^h)</td>
<td>5,658(^h)</td>
<td>5,523(^h)</td>
<td>6,069(^h)</td>
<td>46%</td>
</tr>
<tr>
<td>Total Illicit Drugs(^d)</td>
<td>24,189(^h)</td>
<td>23,115(^h)</td>
<td>25,402(^h)</td>
<td>24,535(^h)</td>
<td>28,409(^h)</td>
<td>35,132(^h)</td>
<td>34,993(^h)</td>
<td>34,807(^h)</td>
<td>35,041(^h)</td>
<td>35,775(^h)</td>
<td>48%</td>
</tr>
</tbody>
</table>

Note: 2002 to 2006 data is based on 2006 National Survey on Drug Use and Health Survey Report.
Figures in () indicate percentage.

a Difference between estimate and 2006 estimate is statistically significant at the 0.05 level.
b Difference between estimate and 2006 estimate is statistically significant at the 0.01 level.
c Estimate is statistically different than previous year.
d Illicit drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutics used nonmedically.


member suffering from the disease of drug or alcohol addiction say their family member has never sought treatment. Of those whose family member has sought treatment, 3 out of 10 only sought treatment after intervention.

♦ Of those whose family member sought treatment, almost half say the family member relapsed and almost one out of 10 say there was no improvement at all.
♦ Only 3 out of 10 respondents say their addicted family member consulted with a medical doctor or other medical professional specializing in the treatment of addiction.
♦ Over half of the respondents say their addicted family member was never evaluated for psychological illness.

The latest Center on Addiction and Substance Abuse (CASA) report (193) also presented alarming statistics finding that at 11 million high school students (80%) and 5 million middle school students (44%) attended drug-infested schools, where they have personally witnessed illegal drug use, illegal drug dealing, and students high on the grounds of the school. More than one in 3 (37%) teens say they can buy marijuana within a day, and 17% say they can buy marijuana within an hour. Even more concerning, students who identify themselves as “popular” and attended a drug-infested school, were 5 times more likely to get drunk in a typical month, and are much more likely to abuse prescription and illegal drugs. It is particularly concerning that 28.9% of pharmacists have been robbed within the past 5 years, and 20.9% no longer stock certain controlled drugs in order to prevent future robberies.

3.4.1 Physician Survey Highlights

In a 2006 survey (194) of 248 primary care physicians (PCP) regarding their attitudes toward the prescribing of opioids for chronic pain, their major concerns included prescription drug abuse (84.2%), addiction (74.9%), adverse effects (68%), tolerance (60.7%), and medication interaction (32%). A majority were comfortable prescribing opioids for cancer pain, but they were less comfortable prescribing opioids for back pain or for patients with a history of drug or alcohol abuse. Only 6.9% reported obtaining a urine screen prior to initiating opioid therapy, and only 15% performed urine screens on patients currently on opioids.

Similarly, in another survey (195) of 111 primary care attendings, residents, and nurse practitioners in 8 community clinics, the PCPs reported that 37.5% of their adult patients in a given week had chronic pain issues. But, they attributed these problems with patient care to patient related factors such as self-management and abuse issues instead of provider or practice system factors.

In a study published in 2007 (196) evaluating long-term opioid contract use for chronic pain management in primary care practice, illustrating a 5-year experience, contracts were discontinued in approximately 40% of the patients. However, only 17% were cancelled for substance abuse and noncompliance and 20% discontinued the contract voluntarily. In this population, urine toxicology screens were obtained in 42% of patients of whom 38% were positive for illicit substances. This report reveals a lack of a systematic approach to opioid administration and monitoring in primary care practices. In another article, it was questioned with regards to the dilemmas experienced when prescribing opioids in general practice (197). There have also been publications with regards to designing a primary care-based chronic pain management program from a scientific basis (198) and guidance for contractual approaches (198). Further, issues related to chronic pain patients, adherence monitoring, etc., have been described in detail in chronic pain management settings (1).

3.4.2 Pharmacist Survey Highlights

There have been no new studies of pharmacists since the CASA study of 2005 (180). At that time, 28.4% of pharmacists did not regularly validate the prescribing physician’s DEA number when dispensing controlled drugs; one in 10 (10.5%) rarely or never do
so. Sixty-one percent did not regularly ask if the patient is taking any other controlled drugs, 25.8% rarely or never do. Seventy-eight percent become "somewhat or very" concerned about diversion or abuse when a patient asks for a controlled drug by name; 83.1% have refused to dispense a controlled drug in the past year because of suspicions of diversion; and 51.8% believed that patients account for the bulk of the diversion problems.

3.4.3 Drug Abuse Warning Network (DAWN) Reports

The Drug Abuse Warning Network (DAWN) (199) examined the involvement of opiates and deaths related to drug misuse. Nearly 1.3 million emergency department (ED) visits in 2005 were associated with drug misuse/abuse (200). Nonmedical use of pharmaceuticals was involved in nearly a half million of these ED visits with opioids constituting over 196,000 visits (an increase over 2004 of 24%). There was a 92% increase in visits due to hydromorphone products (most likely due to Palladone overdoses), and a 29% increase in methadone visits. Two-thirds or more of ED visits associated with opiates/opioids, benzodiazepines, and muscle relaxants involved multiple drugs, and alcohol was one of the other drugs in about a quarter of such visits. Toxic effects were reported in 10% of visits. The DAWN data also showed that opioids account for more overdose deaths in the United States than either heroin or cocaine.

In 2006, young adults aged 18 to 25 demonstrated rates of current use of illicit drugs to be higher (19.8%) than for youths aged 12 to 17 and adults aged 26 or older, with 16.3% using marijuana, 6.4% using psychotherapeutics nonmedically, 2.2% using cocaine, and 1.7% using hallucinogens (Fig. 3).

3.4.4 Healthcare and Social Costs

Unfortunately, the current emphasis on pain assessment as the fifth vital sign has resulted in the potential overmedication of a group of patients (139,140). Prescription drug abuse inflicts enormous costs on our society. The mortality from opioids cannot be ignored (201,202). In a study of the Centers for Disease Control (CDC) (203), increasing deaths were found from opioid analgesics in the United States. Unintentional drug poisoning mortality rates increased an average of 5.3% per year from 1979 to 1990 and 18.1% per year from 1990 to 2002. The rapid increase during the 1990s reflects the rising number of deaths attributed to opioids and unspecified drugs. Between 1999 and 2002 (the last date for which the information is available), the number of opioid analgesic poisonings on death certificates increased 91.2%, while heroin and cocaine poisonings increased 12.4% and

![Fig. 3. Past month use of selected illicit drugs among young adults aged 18 to 25: 2002 – 2006 (1).](image-url)
22.8%, respectively. In 2002, opioid analgesic poisoning was listed in 5,528 deaths – more than either heroin or cocaine. The follow-up evaluation in 2007 (200) revealed that unintentional drug poisoning was second only to motor vehicle crashes as a cause of death from unintentional injury in the United States. This updated study showed the number of unintentional poisoning deaths increased from 12,186 in 1999 to 20,950 in 2004, with an increase of age-adjusted rate of 62.5% from 4.4 per 100,000 population in 1990 to 7.1 in 2004. The highest rate of deaths (59.6) in 2004 were among persons aged 35 to 54 years. Among the opioids, methadone has been implicated in more unintentional poisoning deaths than any other opioid (176,177,204-207).

Methadone-related deaths from 1999 to 2004 increased 390%, whereas the number of all poisoning deaths increased 54% (203). In addition, methadone mentions in poisoning deaths increased from 4% of all poisoning deaths to 13% of all poisoning deaths. The increase in methadone deaths was 29% from 2002 to 2004, in contrast to all poisoning deaths of 6% during the same period (Table 8). Further, persons aged 15 to 24 years contributed to the largest increases of deaths with a rate of 11 times to that of 99 in 2004, even though most methadone deaths were in persons aged 35 to 44 and 45 to 54 years of age. However, reassessment of methadone mortality in 2007 also showed increasing use, misuse, diversion, and abuse (208,209). This led to a stricter warnings about methadone by the FDA (210).

Table 8. Number of poisoning deaths in which specific narcotic substances are mentioned, 1999 to 2004.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Poisoning by all Narcotics and Psychodysleptics</td>
<td>9,995</td>
<td>10,173</td>
<td>11,480</td>
<td>14,247</td>
<td>15,731</td>
<td>16,735</td>
<td>68.1</td>
<td>6.4</td>
</tr>
<tr>
<td>Opium</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>-75.0</td>
<td>-75.0</td>
</tr>
<tr>
<td>Heroin</td>
<td>1,964</td>
<td>1,846</td>
<td>1,782</td>
<td>2,091</td>
<td>2,080</td>
<td>1,881</td>
<td>-4.2</td>
<td>-9.6</td>
</tr>
<tr>
<td>Other Opioids</td>
<td>2,757</td>
<td>2,932</td>
<td>3,484</td>
<td>4,431</td>
<td>4,877</td>
<td>5,242</td>
<td>90.1</td>
<td>7.5</td>
</tr>
<tr>
<td>Methadone</td>
<td>786</td>
<td>988</td>
<td>1,456</td>
<td>2,360</td>
<td>2,974</td>
<td>3,849</td>
<td>389.7</td>
<td>29.4</td>
</tr>
<tr>
<td>Other Synthetic Narcotics</td>
<td>732</td>
<td>784</td>
<td>962</td>
<td>1,301</td>
<td>1,406</td>
<td>1,668</td>
<td>127.9</td>
<td>18.6</td>
</tr>
<tr>
<td>Cocaine</td>
<td>3,832</td>
<td>3,565</td>
<td>3,840</td>
<td>4,612</td>
<td>5,212</td>
<td>5,461</td>
<td>42.5</td>
<td>4.8</td>
</tr>
<tr>
<td>Other Narcotics</td>
<td>2,902</td>
<td>2,880</td>
<td>2,881</td>
<td>3,143</td>
<td>3,117</td>
<td>2,761</td>
<td>-4.9</td>
<td>-11.4</td>
</tr>
<tr>
<td>Cannabis</td>
<td>37</td>
<td>41</td>
<td>37</td>
<td>50</td>
<td>61</td>
<td>99</td>
<td>167.6</td>
<td>62.3</td>
</tr>
<tr>
<td>LSD</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>-66.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Other</td>
<td>9</td>
<td>8</td>
<td>7</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>-44.4</td>
<td>-16.7</td>
</tr>
</tbody>
</table>

Note: Substance-specific data are not additive because of death.
Source: National Center for Health Statistics, National Vital Statistics System

3.5 Substance Abuse in Chronic Pain

The central question when prescribing opioids for chronic, non-cancer pain is how best to balance the risk of opioid abuse with the pain relief provided by these medications (7,159).

A prospective cohort study of 196 opioid treated, chronic, non-cancer pain patients identified predictors of opioid misuse (160). Misuse was defined as having: negative urine toxicologic screen (UTS) for prescribed opioids, UTS positive for controlled substances not prescribed, procurement of opioids from multiple providers, diversion of opioids, prescription forgery, or, UTS positive for stimulants. The strongest predictors of misuse were the self-reported histories of previous alcohol or cocaine abuse, or previous criminal drug or alcohol-related convictions. Demographics such as gender, race, literacy, disability, and socioeconomic status were not associated with misuse.

The Veterans Administration looked at longitudinal administrative data from 2000 to 2005 (15,000 patients), and found that nonopioid substance abuse (such as alcohol) was the strongest predictor of opioid abuse (211). Mental health disorders were moderately strong predictors; the incidence of mental health disorders was much higher than the prevalence of nonopioid substance abuse (45.3% vs 7.6%), suggesting that mental health disorders were indicative of a higher risk. Males, younger adults, and individuals with greater days supply of prescription opioids were more likely to develop opioid abuse. To look at the issue from the other side, a representative sample of
390 patients from 2 methadone maintenance treatment programs (MMTP) revealed that 37% of these patients suffered from severe, chronic pain (212). Correlates of chronic pain included age (odds ratio [OR] 2.08), chronic illness (OR 1.88), and lifetime psychiatric illness (OR 1.77).

Fleming et al (189) in a sample of primary care patients found that the frequency of opioid use disorders was 4 times higher in patients receiving opioid therapy compared to nonopioid therapy patients. They also showed that DSM-IV evidence of opioid use disorder was seen in 9.7% of patients, 4 times higher than the reported general population, and 24% of urine drug testings were positive for illicit drugs.

Even though occasional studies (213) and proponents claim extremely low levels of opioid abuse, opioids are by far the most abused drugs, especially in chronic pain management settings. Numerous investigations have illustrated drug abuse in 18% to 41% in patients receiving opioids for chronic pain (1-5,10,146-163,214-216).

Martell et al (10) in a systematic review of opioid treatment for chronic back pain, estimated the prevalence of lifetime substance use disorders to range from 36% to 56%, with a 43% current substance use disorder rate. Further, aberrant medication-taking behaviors ranged from 5% to 24%.

The abuse of drugs in chronic pain patients may also include illicit drugs in conjunction with controlled substances. Multiple investigators have studied the issue of illicit drug use in chronic pain patients receiving controlled substances (146,158,160-163). The results showed that illicit drug use in patients without controlled substance abuse was found in 14% to 16% of patients and illicit drug use in patients with controlled substance abuse was present in 34% of the patients (148,150,151). Illicit drug use was significant in chronic pain patients in general, but illicit drug use was similar in patients using either long-acting or short-acting opioids (161). In other evaluations, it was shown that adherence monitoring will in fact decrease controlled substance abuse and illicit drug use (158,163).

Along with the increase of prescriptions for controlled drugs from 1992 to 2002 of 154% (173-175,215-218), there was also a 90% increase in the number of people who admitted abusing controlled prescription drugs (219). Studies also evaluated opioid abuse in the insured population of the United States (218). Opioid abuse was determined to be present in 6.7 to 8 per 10,000 persons insured however, opioid abusers presented with multiple comorbidities and expenses 8 times higher than for non-abusers ($15,884 vs $1,830).

### 3.6 Economic Impact

The cost of opioid abuse is enormous ranging as high as $300 billion a year as per the estimates of the White House Budget Office. The White House Office of National Drug Control Policy, a component of the Executive Office of the President, established by the Anti-Drug Abuse Act of 1990, has been spending $12 to $13 billion each year (2).

A study by the Office of Management and Budget estimated drug abuse costs to the United States at $300 billion a year, including government anti-drug programs and the costs of crime, healthcare, accidents, and lost productivity. In the Aid to Family with Dependent Children (AFDC), Medicaid and food stamp programs, the incidence of drug abuse varies from 9.4% to 16.4% (218).

### 3.7 Drug Diversion

Drugs can be diverted from their lawful purpose to illicit use at any point in the pharmaceutical manufacturing and distribution process. The diversion of prescription drugs among adults is typically described to occur through one of the following: doctor shopping, illegal internet pharmacies, drug theft, prescription forgery, and illicit prescriptions by physicians. Youths typically acquire drugs by stealing from their relatives or buying from classmates who sell their legitimate prescriptions.

For the SAMHSA surveys (190,191), nonmedical users of prescription-type psychotherapeutic drugs were asked questions regarding how they obtained the drugs they recently used nonmedically. In both 2005 and 2006, over half of the nonmedical users of prescription-type pain relievers, tranquilizers, stimulants, and sedatives said they obtained the drugs they used most recently “from a friend or relative for free.” A follow-up question added in 2006 asked these respondents where their friend or relative had obtained the drugs. In 80.7% of the cases, the individuals indicated that their friend or relative had obtained the drugs from just one doctor. Only 1.6% reported that the friend or relative had bought the drug from a drug dealer or other stranger (Fig. 4).

As long as long-acting forms of opioids can be converted into rapid-onset drugs, there will be a push to divert and abuse these medications (221). In
the wake of the OxyContin abuse scandals, the FDA has added warning labels to extended release formulations, admonishing against crushing and chewing tablets, which may have led to increased experimentation and abuse (222). The ease with which an active ingredient can be extracted from the parent medication has been seen as related to the medication’s abuse potential; unfortunately, the pharmacy industry currently lacks standards to assess the tamper-resistance of a formulation, which makes it difficult to compare different formulations from different manufacturers. Katz and colleagues (223) have proposed 4 components of extractability: ease of extraction, purity of extract, efficiency of extraction, and potency of extract. They then developed a rating system, but concluded that more work needed to be done on the system before it could be used as an industry standard.

Doctor shopping by drug abusers is one of the most common ways of getting illegal controlled substances (224). Generally, this term refers to the visit by an individual—who may or may not have legitimate medical needs—to several doctors, each of whom writes a prescription for a controlled substance. The individual will visit several pharmacies, receiving more of the drug than intended by any single physician, typically for the purpose of feeding an addiction. Other illegal activities may include forged prescriptions and “pill mills” (facilities that prescribe large volumes of opioids without legitimate purpose, often for cash).

Illegal internet pharmacies have been available since about 1999. MarkMonitor, a company that analyzes online brands, estimates that consumers may be spending $4 billion annually on prescription medicines at uncertified online websites linked to spam emails (225). Of the 3,160 sites identified in the report, a third are ranked by the Alexa website tracking service as high volume sites and had an average of 32,000 visitors a day. MarkMonitor estimated that if just 0.5% of customers purchased on average $70 worth of medications, these ranked sites alone would earn $4 billion a year.

Note: Totals may not total to 100% because of rounding or because suppressed estimates are not shown.
1The Other category includes the sources: “Wrote Fake Prescription,” “Stole from Doctor’s Office/Clinic/Hospital/Pharmacy,” and “Some Other Way.”

Fig. 4. Where pain relievers were obtained for most recent nonmedical use among past year users aged 12 or older: 2006 (1).
3.8 Controlling Diversion and Abuse

For nearly 100 years, the laws governing the prescribing of medications with addictive potential (as described in the Harrison Narcotics Act of 1914) worked relatively well to control the access of these medicines while at the same time controlling their misuse. However, recent technological developments, such as internet prescribing, have loosened the controls and increased the rate of diversion and abuse (226).

3.8.1 Drug Enforcement Administration

The Drug Enforcement Administration (DEA), as an agency within the United States Department of Justice, is the lead federal law enforcement agency responsible for enforcing the Controlled Substance Act (CSA). In cooperation with state authorities and other federal agencies, the DEA is responsible for preventing the diversion of controlled substances for illicit purposes. However, the DEA must comply with international treaties to the extent that they are not in conflict with constitutional provisions; it must also work closely with foreign, state, and local governments. The DEA has increased its monitoring of internet prescription drug sales. DEA investigations, enforcement, and intelligence programs have started to work more closely with other federal, state, and local agencies to target individuals and organizations involved in diversion and abuse of controlled prescription drugs.

High-profile arrests and prosecutions focus physicians’ attention on the risks entailed in prescribing controlled substances in general, and have the specific effect of increasing physicians’ and pharmacists’ reluctance to prescribe, stock, or dispense opioid analgesics (227). However, a study published in 2006 looked at DEA arrest records in an effort to gauge the actual risk of DEA action (228). The review of the arrests and administrative actions of the DEA during fiscal year 2003 and 2004 showed that of the 963,385 physician registrants, there were 557 investigations with 6 civil fines, 22 letters of admonition, 21 administrative hearings, 34 license revocations, and 45 arrests.

3.8.2 State Laws and Regulations

Neither the DEA nor the federal government has the authority to regulate medical practice; this is the sole responsibility of the state government. States can require that a drug prescription be filled within a specified amount of time after it is written, and they can classify drugs at a higher level of abuse risk than the CSA schedule or place the drug on a state controlled substance list if not on the CSA list. State policies may conflict with or hamper the implementation of current treatment guidelines for the management of pain by limiting the amounts of opioid medications that can be prescribed, requiring special government-issued prescription forms, using outdated terminology, considering opioids only as the treatment of last resort, and suggesting incorrectly that the therapeutic use of opioids hastens death (229). State medical boards can address physician concerns about regulatory scrutiny and promote the balance between opioid benefits and risks. Before 1989, only a few state medical boards developed policies governing the use of controlled substances (230). Since then, 41 states have adopted such policies, which include regulations that have the force of law, as well as guidelines and policy statements.

3.8.3 Prescription Drug Monitoring Programs

States began to address the misuse and abuse of prescription medications in the 1940s by creating programs to monitor the dispensing of prescription drugs (3). These early programs required physicians to use special multiple-copy, 2- or 3-part prescription order forms, with a copy sent to a state monitoring program, and they only monitored Schedule II drugs. By 1999, 15 states had adopted prescription drug monitoring programs; but they were quite diverse. By the 1990s some programs were able to initiate electronic reporting, but, paper or electronic, most still used a variety of triggers such as number of prescriptions written or volume of medications prescribed to “flag” physicians or patients for further investigation. Kentucky established the Kentucky All Scheduled Prescription Electronic Reporting program (KASPER), an effective program that was limited by the 7 border states that surround Kentucky, allowing patients to take their prescriptions across state lines to thwart the program.

President Bush signed the National All Scheduled Prescription Electronic Reporting (NASPER) Act on August 11, 2005, making it the only statutorily authorized program to assist states in combating prescription drug abuse of controlled substances through a PDMP, and authorizing the U.S. Department of Health and Human Services (HHS) to award grants to States to construct prescription drug monitoring programs (PDMPs) and enhance communications between existing ones. Unfortunately, funding has not been provided for this activity (3).

A review of monitoring opioid adherence in chronic pain patients describes PDMPs (159). However, the effect and effectiveness of PDMPs is difficult to ascertain. The Medical Expenditure Panel survey showed
Opioids are analgesics compounds that attach to and modulate ascending and descending pain related pathways (231). Opioids may be classified by their function as agonists, mixed agonists-antagonists, or antagonists, and by their actions at opioid receptors, mu, kappa, and delta (231,232). Compounds can have differing degrees of affinity and efficacy at these various receptors (233).

4.1.1 Opioid Receptors

There are opioid receptors within the central nervous system as well as throughout the peripheral tissues. These receptors are normally stimulated by endogenous peptides (endorphins, enkephalins, and dynorphins) produced in response to noxious stimulation. In addition, peripherally acting opioids (234) and combination of opioid analgesics have been described (235). Table 9 provides opioid receptors, related indigenous peptides, agonists, agonist/antagonist, and antagonists.

The opioid receptors were discovered in 1972, and the first endogenous opioid (enkephalin) was discovered in 1975. Their location in the CNS allows them to function as neurotransmitters, altering hormone secretion, thermoregulation, and cardiovascular control.

Opioids are classified by their action. These agents exhibit varying degrees of receptor affinity and efficacy, and can be pure agonist, agonist/antagonist, or antagonist.

Pure opioid agonists (e.g., morphine, hydromorphone, fentanyl) stimulate mu receptors and are the most potent analgesics. As the dose is increased, analgesia occurs in a log linear fashion; the degree of analgesia induced is limited only by intolerable dose-related adverse effects. Partial agonists and agonist/antagonists (example, nalorphine) exhibit a ceiling effect on the degree of analgesia that they can produce. Antagonists, as the name implies, counteracts effects at the opioid receptor.

4.1.2 Opioid Categories

The DEA classifies opioids into schedules related to potential abuse, and not potency (Table 10).

There has been concern that the lower scheduled opioids (Schedule III and IV) might have a higher addictive potential than some of the higher scheduled opioids (Schedule II). In a recent study (236), it was suggested that shorter-acting opioids had a lower potential for abuse. They looked at 140 patients on long-acting opioids (Schedule II) compared to 687 patients on short-acting opioids and 225 patients on nonopioids. More of the long-acting opioid patients (38%) were discharged from the practice for non-compliance compared to the short-acting opioid patients (32%) or the nonopioid patients (30%). In another study (161) in an interventional pain management setting evaluating the abuse of prescription and illicit drugs in chronic pain patients receiving either short-acting (hydrocodone) or long-acting (methadone), they concluded that prescription drug abuse as well as illicit drug use was similar in both groups of patients.

4.1.3 Opioid Metabolism

Many of the side effects of opioids, as well as their effects, may be related to the opioid metabolites. Most of the metabolism of opioids occurs in the liver. The CYP450 enzymes are a super-family of heme-containing, microsomal drug-metabolizing enzymes that are important in the biosynthesis and degradation of a wide variety of endogenous compounds, chemicals, toxins, and medications. More than 2,700 individual members of the CYP450 super-family have been identified, and 57 cytochrome P450 enzymes are recognized in humans (237). CYP3A4 is the isoenzyme most frequently involved in drug metabolism, and accounts for a broad range of substrates. The metabolism of opioids is complex, involving multiple enzymes and pathways, which can lead to significant inter-individual variability in drug disposition.
for approximately 50% of marketed drug metabolism, and levels of CYP3A4 may vary as much as 30-fold between individuals (238), leading to large variability in blood levels. The metabolism of more than 90% of the most clinically important medications can be accounted for by 7 CYP isozymes (3A4, 3A5, 1A2, 2C9, 2C19, 2D6, and 2E1) (239). CYP1A2, CYP2C8, and CYP2C9 make up about 10% of the enzymes, CYP2D6 and CYP2E1 each around 5%, and CYP2C19 around 1%. CYP2D6 is entirely absent in some populations; for example, 6–10% of Caucasians are 2D6 deficient (240), while other persons have high levels of this enzyme, leading to rapid metabolism of the medicines.

4.2 Adverse Effects
Complications due to opioid administration concern all medical practitioners (7,8). Commonly known side effects of opioids include constipation, pruritus, respiratory depression, nausea, vomiting, delayed gastric emptying, sexual dysfunction, muscle rigidity and myoclonus (may be present in 3 to 87% of cancer patients, may be mediated by glycine inhibition in the dorsal horn neurons, and may be treated by opioid reduction or rotation, as well as benzodiazepines and baclofen) (241,242), sleep disturbance (243) (morphine has been shown to reduce REM sleep via inhibition of acetylcholine release in the reticular activating formation (244), pyrexia, diminished

Table 9. Illustration of activity of opioid receptors.

<table>
<thead>
<tr>
<th>Mu (µ)</th>
<th>Delta (Δ)</th>
<th>Kappa (κ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Mu 1 – Analgesia</td>
<td>• Analgesia, spinal analgesia</td>
<td>• Analgesia, sedation, dyspnea, psychomimetic effects, miosis, respiratory depression, euphoria, dysphoria, dyspnea</td>
</tr>
<tr>
<td>• Mu 2 – Sedation, vomiting, respiratory depression, pruritus, euphoria, anorexia, urinary retention, physical dependence</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endogenous Peptides

<table>
<thead>
<tr>
<th>Enkephalin</th>
<th>Agonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Endorphin</td>
<td>Agonist</td>
</tr>
<tr>
<td>Dynorphin A</td>
<td>Agonist</td>
</tr>
</tbody>
</table>

Agonists

<table>
<thead>
<tr>
<th>Morphine</th>
<th>Agonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td>Weak agonist</td>
</tr>
<tr>
<td>Fentanyl, sufentanil,</td>
<td>Agonist</td>
</tr>
<tr>
<td>Meperidine</td>
<td>Agonist</td>
</tr>
<tr>
<td>Methadone</td>
<td>Agonist</td>
</tr>
</tbody>
</table>

Agonist-antagonists

<table>
<thead>
<tr>
<th>Nalorphine</th>
<th>Agonist-antagonist</th>
</tr>
</thead>
</table>

Antagonists

<table>
<thead>
<tr>
<th>Naloxone</th>
<th>Agonist-antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naltrexone</td>
<td>Agonist-antagonist</td>
</tr>
</tbody>
</table>

Table 10. DEA schedules of controlled drugs.

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Criteria</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>No medical use; high addiction potential</td>
<td>Heroin, marijuana, PCP</td>
</tr>
<tr>
<td>II</td>
<td>Medical use; high addiction potential</td>
<td>Morphine, oxycodone, methadone, fentanyl, amphetamines</td>
</tr>
<tr>
<td>III</td>
<td>Medical use; moderate addiction potential</td>
<td>Hydrocodone, codeine, anabolic steroids</td>
</tr>
<tr>
<td>IV</td>
<td>Medical use; low abuse potential</td>
<td>Benzodiazepines, meprobamate, butorphanol, pentazocine, propoxyphene</td>
</tr>
<tr>
<td>V</td>
<td>Medical use; low abuse potential</td>
<td>Buprenex, phenergan with codeine</td>
</tr>
</tbody>
</table>
4.3 Drug Interactions

A drug interaction occurs when the amount or the action of a drug is altered by the administration of another drug or multiple drugs. Multiple hepatic drug interactions may influence opioid drug levels (8,231,232) as illustrated in Table 11.

4.4 Drug Conversions

While there have been multiple opioid conversion charts developed, none are reliable and none take into consideration the vast individual differences in effect and metabolism between patients and within medications. Brand name and generic medications may have significant differences in bioavailability, and metabolism of medications may be influenced by genetic polymorphism and drug interactions. It is therefore important to recognize that “equipotent” doses of medications may have very different degrees of analgesia and side effects. In general, to switch between medications, the clinician must calculate a rough equiva-

Table 11. Drug interactions of opioids.

<table>
<thead>
<tr>
<th>Drug Interaction</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tricyclic antidepressants</td>
<td>Inhibit morphine glucuronidation leading to ↑blood levels --- Nortriptyline inhibits noncompetitively --- Amitriptyline and clomipramine inhibit competitively</td>
</tr>
<tr>
<td>Methadone and morphine</td>
<td>↓metabolism of TCAs, leading to toxicity</td>
</tr>
<tr>
<td>Quinine</td>
<td>↓conversion of codeine to morphine leading to ↓analgesia</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Earlier peak plasma levels with controlled-released opioids</td>
</tr>
<tr>
<td>Meperidine</td>
<td>MAO inhibitors trigger hyperpyrexia</td>
</tr>
<tr>
<td>Propoxyphene</td>
<td>↑carbamazepine, doxepin, metoprolol, propranolol levels ↓excretion of benzodiazepines, leading to accumulation and overdose</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>↑opioid effects</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>↑methadone levels</td>
</tr>
<tr>
<td>Rifampin, Phenytoin, Carbamazepine</td>
<td>↓methadone levels</td>
</tr>
<tr>
<td>Phenytoin, Phenobarbital</td>
<td>↓meperidine levels</td>
</tr>
<tr>
<td>CY2D6 inhibitors</td>
<td>↑tramadol levels ↓analgesia from hydrocodone/codeine</td>
</tr>
<tr>
<td>CY2D6 substrates</td>
<td>↑tramadol levels because of competition for metabolism</td>
</tr>
<tr>
<td>CYP3A4 inhibitors</td>
<td>↑methadone levels</td>
</tr>
<tr>
<td>CYP3A4 inducers</td>
<td>↓methadone levels</td>
</tr>
<tr>
<td>Methadone and morphine</td>
<td>↓metabolism of desipramine, leading to toxicity</td>
</tr>
</tbody>
</table>
lent 24-hour dose, divide by the dosing schedule, and then “under-dose,” especially with methadone, with subsequent titration to effect.

4.5 Opioid Therapy and Side Effects

Multiple reviews (231-235,250) described opioid pharmacology of agonists, antagonists, partial agonists, agonists and antagonists, peripherally-acting opioids, combination opioid analgesics, and variations in opioid responsiveness. Implications and side effects of long-term opioid therapy include opioid-induced immunologic effects, hormonal changes, hyperalgesia, sedation, sleep disturbances, psychomotor disturbances, constipation, bladder dysfunction, and cardiac effects (8). Opioid complications and side effects in detail along with appropriate management of these side effects were described (8).

5.0 Terminology of Abuse and Addiction

5.1 Introduction

The terminology related to abuse and addiction of opioids and other controlled substances is considered confusing and reflects lack of understanding of multiple issues related to abuse and addiction. There are 3 fundamental concepts related to addiction:
1) the determination of addiction rests with the user even though some drugs produce pleasurable reward;
2) addiction is a multidimensional disease with neurobiological and psychosocial dimensions; and
3) addiction is a phenomenon distinct from physical dependence and tolerance.

Addiction is related to the “reward center” located within the mesocorticlimbic dopamine systems in the brain (251). Up-regulation of cAMP pathways in the brain (locus coeruleus) and spinal cord leads to acute physical withdrawal symptoms when the administered opioid is reduced or stopped, resulting in excessive central norepinephrine release, and its manifestations (252). Addiction is therefore a physiologic response, influenced by a variety of psychosocial issues (such as depression and anxiety) as well as genetic issues (family history of addiction).

5.2 History

More than a century ago, the debate over how best to address the misuse and abuse of prescription medications began, at a time when the most commonly abused drugs were freely available (253). As an example, heroin (diacetyl morphine) was developed to help morphine addicts; “heroin was sold over the counter as a soothing syrup for colicky babies and cocaine was the reason a then-new beverage invented in an Atlanta pharmacy was called ‘Coke’ (254).”

5.3 Terminology

Despite significant growth in understanding of the scientific basis of addiction, definitions and diagnostic criteria based on obsolete conceptualization of addiction persist. The following terms have been defined by World Health Organization (WHO), DSM-IV, and United States Federal and State policies, and other organizations by means of consensus statements.

There continues to be confusion and misunderstanding concerning the term “addiction.” The Controlled Substance Act defined addiction as a term meaning any individual who habitually uses any narcotic drug so as to endanger the public morals, health, safety, or welfare or who is so far addicted to the use of narcotic drugs as to have lost the power of self-control with reference to his or her addiction (255).

5.3.1 Substance Abuse

DSM-IV defines substance abuse as a maladaptive pattern of substance use leading to significant impairment or distress in the last 12 months with one (or more) events such as failure to fulfill major role obligations, using inappropriate substances, participating in hazardous situations, being involved in recurrent substance related legal problems, and/or continuing use in the face of adverse consequences.

5.3.2 Substance Dependence

DSM-IV defines substance dependence as a maladaptive pattern of substance use leading to significant impairment or distress in the last 12 months meeting the criteria for substance abuse plus 3 or more of the following 7 criteria during the same 12-month period: tolerance, withdrawal, inability to control use, unsuccessful attempts to decrease or discontinue use, a great deal of time lost in obtaining the substance, using the substance, or recovering from its effects, important activities are given up because of use, continued use despite physical or psychological problems caused by use, and continued use of a substance.

5.3.3 Tolerance

The need for an increased dosage of a drug to produce the same level of analgesia that previously existed is defined as tolerance. Tolerance also suspect-
Ed when a reduced physiologic effect is observed with constant dosing. Analgesic tolerance is not always evident during opioid treatment, and is not to be confused with addiction, which occurs as a dysfunctional craving of a drug action by physiologic action and psychologically driven factors.

5.3.4 Withdrawal

Withdrawal describes a characteristic set of symptoms that occur when a substance is withdrawn, and those symptoms disappear when the substance is reintroduced.

5.3.5 Physical Dependence

Physical dependence is a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by a drug cessation, rapid dose reduction, decreasing blood level of the

Fig. 5. Contributions to addiction. Adapted from Ballantyne (6). Opioid analgesia: Perspectives on right use and utility. Pain Physician 2007; 10:479-491.
drug, and/or administration of an antagonist. Physical dependence is a normal adaptation to the drug, reinforced by continued use. Physical dependence is most commonly associated with withdrawal symptoms when the substance is abruptly discontinued, and is seen in many classes of medication not associated with addiction, such as beta blockers.

5.3.6 Addiction

In contrast to tolerance, withdrawal, and physical dependence, addiction is compulsive use of a drug despite physical harm, and the terms tolerance and addiction are not interchangeable. The terminology may share similar characteristics, as many addicts do become tolerant of their chosen drug, which can be expected with regular use. Addiction is a dysfunctional use behavior that includes one or more of the following: impaired control over drug use, compulsive use, continued use despite harm and craving, while tolerance is a physiologic alteration of metabolism.

In a chronic pain state, a patient may be exposed to a controlled substance for a prolonged period of time, developing tolerance and physical dependence. Addiction may occur, but is an unlikely event. Dependence does not foreshadow harm, or intent at self-destructive behavior. It is therefore, incumbent upon the pain management physician to determine that these definitions and their physiologic undertones are well understood, and that the overlap of these definitions does not necessarily define a controlled substance risk or an inappropriate patient. In other words, tolerance and dependence share many common physiologic characteristics, and addiction may be associated with, but not defined by, either or both. Physical dependence, addiction, and tolerance are physiologic, social, and psychological considerations with prolonged substance management.

5.4 Opioid Agonist Therapy

Opioid agonist therapy (OAT) is a term used when a prescribed drug is given to occupy the receptor sites that otherwise would respond to an illicit agent such as heroin (229). OAT is a widely accepted medical treatment for opioid addiction, with efficacy that has been documented in many studies over many years (256). The best-known and most widely used form of OAT involves methadone maintenance treatment (MMT), though a second and newer form of OAT employs buprenorphine (a partial agonist), which is able to block the effects of morphine and other opioids, while offering mild opioid-like effects (232,257).

6.0 CLINICAL EFFECTIVENESS

6.1 Introduction

Considerable controversy over the prescription of opioids for chronic non-cancer pain continues despite the growing acceptance of this practice and claims that pain is undertreated. WHO developed a step-ladder approach to the management of pain. It recommends nonopioid analgesics initially, and then suggests the addition of mild opioids (e.g., hydrocodone) for mild to moderate pain, reserving strong opioids such as morphine for severe pain (258). In addition, opioids have been endorsed by multiple societies and advocacy organizations as appropriate treatment for refractory chronic non-cancer pain in the general population, when used judiciously and according to guidelines similar to those used for cancer patients. The DEA has also taken the position that clinicians should be knowledgeable about using opioids to treat pain, and should not hesitate to prescribe them when opioids are the best clinical choice of treatment (255). However, these endorsements of opioids in chronic non-cancer pain vary widely based on the philosophy of organizations, advocacy, ethical, and financial interests. Variations are evident with regards to the selection criteria, documentation, drug dosages, frequency, duration, and break through pain management. While all agree that opioids are indicated in cancer pain, numerous questions continue to arise about opioid usage in non-cancer pain on a long-term basis. Consequently, there is wide disagreement on who should be treated, how much should be provided, and who should be monitoring the controlled substances, their abuse, diversion, and side effects.

The clinical effectiveness of opioid medications for non-cancer pain in humans is difficult to measure. Since the publication of the ASIPP Opioid Guidelines by Trescot et al (1) in 2006, several new studies, including systematic reviews, observational studies, and controlled trials, evaluated the clinical effectiveness of medications.

6.2 Systematic Reviews

As illustrated in Table 3 and Fig. 1, from 1997 to 2006 the use of methadone increased exponentially followed by oxycodone, fentanyl base, hydromorphone, hydrocodone, morphine, and codeine. However, the highest use of per milligram per person in the United States for 2006 was methadone followed by oxycodone, fentanyl, hydrocodone, and morphine (Table 4).
Further, the proportion of the highest use of opioids is oxycodone, followed by hydrocodone, whereas the highest growth is in methadone with an increase of 1,129% from 1997 to 2006 (Table 4) (5).

The available evidence is highly variable. There is literature support for long-term use of opioids in chronic non-cancer pain with improvement in function and reduction in pain for longer than 6 months for transdermal fentanyl and sustained-release morphine (albeit weak) (9,19). However, the evidence is limited for the most commonly used opioid, i.e., oxycodone, in the United States. Further, for the second most commonly used opioid in the United States, hydrocodone, the evidence is non-existent. The evidence for methadone and other drugs is also non-existent. This lack of evidence for the most commonly used opioids and weak evidence for morphine and transdermal fentanyl are insurmountable factors in the synthesis of evidence-based guidelines for opioid use for long-term management of chronic non-cancer pain.

Noble et al (9) in a systematic review and meta-analysis of efficacy and safety of long-term opioid therapy for chronic non-cancer pain, published in 2008, reviewed the clinical evidence on patients treated with opioids for chronic non-cancer pain for at least 6 months. They identified 115 studies from 11 databases until April 7, 2007. Of these, 17 studies met the inclusion criteria. Seven studies of 1,504 patients evaluated oral opioids (259-265), whereas 3 studies with 1,993 patients (259,266,267) evaluated transdermal opioids. Table 12 illustrates characteristics of the included studies in the evaluation of long-term effectiveness by Noble et al (9).

<table>
<thead>
<tr>
<th>Reference</th>
<th>Opioid</th>
<th>Type of Predominant Pain</th>
<th>Number of Patients Enrolled</th>
<th>Withdrawal Due to Adverse Events</th>
<th>Withdrawal Due to Insufficient Pain Relief</th>
<th>Pain Continuous/Categorical</th>
<th>&gt;50% Relief</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allan et al (259)</td>
<td>Morphine</td>
<td>Low back pain</td>
<td>342</td>
<td>✓</td>
<td>✓</td>
<td>b</td>
<td>✓</td>
</tr>
<tr>
<td>Caldwell et al (260)</td>
<td>Morphine</td>
<td>Osteoarthritis</td>
<td>(295)/181</td>
<td>✓</td>
<td>✓</td>
<td>d</td>
<td></td>
</tr>
<tr>
<td>Harati et al (261)</td>
<td>Tramadol</td>
<td>Diabetic neuropathy</td>
<td>(131)/117</td>
<td>✓</td>
<td>✓</td>
<td>c</td>
<td>✓</td>
</tr>
<tr>
<td>Fredheim et al (262)</td>
<td>Methadone</td>
<td>Low back pain</td>
<td>12</td>
<td>✓</td>
<td>✓</td>
<td>e</td>
<td></td>
</tr>
<tr>
<td>McIlwain and Ahdieh (263)</td>
<td>Extended-release oxymorphone</td>
<td>Osteoarthritis</td>
<td>(491)/153</td>
<td>✓</td>
<td>✓</td>
<td>f</td>
<td></td>
</tr>
<tr>
<td>Roth et al (264)</td>
<td>Controlled-release oxycodone</td>
<td>Osteoarthritis</td>
<td>(133)/106</td>
<td>✓</td>
<td>✓</td>
<td>g</td>
<td></td>
</tr>
<tr>
<td>Zenz et al (265)</td>
<td>Dihydrocodeine,a buprenorphine, or morphine</td>
<td>Neuropathic or back pain</td>
<td>100</td>
<td>✓</td>
<td>✓</td>
<td>h</td>
<td></td>
</tr>
<tr>
<td><strong>Transdermal Administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allan et al (259)</td>
<td>Fentanyl</td>
<td>Low back pain</td>
<td>338</td>
<td>✓</td>
<td>✓</td>
<td>b</td>
<td></td>
</tr>
<tr>
<td>Milligan et al (266)</td>
<td>Fentanyl</td>
<td>Unspecified</td>
<td>532</td>
<td>✓</td>
<td>✓</td>
<td>f</td>
<td></td>
</tr>
<tr>
<td>Mystakidou et al (267)</td>
<td>Fentanyl</td>
<td>Unspecified</td>
<td>529</td>
<td>✓</td>
<td>✓</td>
<td>g</td>
<td></td>
</tr>
</tbody>
</table>

a Sustained release.
b Not analyzed because of number of patients at follow-up times not reported.
c N in parentheses denotes number of patients randomized in original RCT; second number is that enrolled in open-label extension.
d Not meta-analyzed because reported units are statistically incompatible with the 3 other studies meeting inclusion criteria.
e Not analyzed because data were reported for fewer than 10 patients at follow-up times.
f Not analyzed because instrument used not validated.

The effectiveness of morphine and transdermal fentanyl by Noble et al (9). Trescot et al (19) evaluated specifically the role long-term opioid therapy.

Tables 13 and 14 illustrate the effectiveness of long-term sustained-release morphine and transdermal fentanyl. They concluded that sustained-released morphine and transdermal fentanyl provided weak

Table 13. Results of studies evaluating the long-term effectiveness of morphine.

<table>
<thead>
<tr>
<th>Study/ methods</th>
<th>Participants</th>
<th>Opioids studied</th>
<th>Outcome(s)</th>
<th>Result(s)</th>
<th>Conclusion(s)</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan et al (259)</td>
<td>Chronic low back pain N=680</td>
<td>Sustained release oral morphine versus transdermal fentanyl</td>
<td>Pain relief; bowel function, quality of life, disease progression, and side effects</td>
<td>Significant proportion of patients on sustained release morphine experienced pain relief</td>
<td>Sustained release strong opioids can safely be used in opioid naïve patients</td>
<td>Most common adverse events leading to discontinuation were nausea (37%), vomiting and constipation.</td>
</tr>
<tr>
<td>Caldwell et al (260)</td>
<td>184 with chronic osteoarthritis</td>
<td>Placebo, Avinza, or MS Contin in double-blind trial</td>
<td>Pain relief; physical functioning; stiffness</td>
<td>Significant improvement in pain relief and sleep measures</td>
<td>Efficacy was comparable between two modes of administration.</td>
<td>Most common adverse effects were constipation and nausea</td>
</tr>
<tr>
<td>Zenz et al (265)</td>
<td>100 patients who were chronically given opioids for treatment of nonmalignant pain, with 23 patients receiving morphine SR</td>
<td>Sustained release morphine, sustained release dihydrocodeine, buprenorphine</td>
<td>VAS, Karnofsky Performance Status Scale used to assess function</td>
<td>Good pain relief was obtained in 51 patients and partial pain relief was reported by 28 patients. Only 21 patients had no beneficial effect from opioid therapy</td>
<td>Results indicate that opioids can be effective in chronic nonmalignant pain, with side effects that are comparable to those that complicate the treatment of cancer pain</td>
<td>Common side effects were constipation and nausea</td>
</tr>
<tr>
<td>Maier et al (296)</td>
<td>121 patients with chronic non-cancer pain</td>
<td>Sustained release morphine</td>
<td>Pain relief and quality of life</td>
<td>Significantly lower pain intensity and improved physical state and quality of life</td>
<td>Pain relief correlated with improvement in functional status</td>
<td>There was no development of tolerance</td>
</tr>
<tr>
<td>Tassain et al (297)</td>
<td>28 chronic non-cancer pain patients, 18 received oral sustained morphine, 10 patients stopped morphine due to side effects and were followed as control group</td>
<td>Oral sustained morphine</td>
<td>Pain relief and cognitive functioning Follow-up period of 12 months</td>
<td>Morphine produced persistent pain relief and improved quality of life and mood</td>
<td>There was no impairment of any neuropsychological variables over time</td>
<td>Side effects included constipation, loss of appetite, nausea, dry mouth, drowsiness, somnolence, fatigue, subjective memory impairment, sweating, and pruritus</td>
</tr>
</tbody>
</table>

evidence for improvement in physical status and decrease in pain on a long-term basis, whereas tramadol provided weak evidence in osteoarthritis patients. However, the most commonly used, oxycodone, provided only limited evidence, while the second most commonly used, hydrocodone, had no published evidence. Similarly, other commonly used opioids had no published evidence of effectiveness with long-term therapy.

Overall, many patients withdrew from the clinical trials due to adverse effects with 32.5% with oral therapy and 17.5% with transdermal therapy; 11.9% in the oral therapy group and 5.8% in the transdermal group withdrew due to insufficient pain relief. They concluded that there was an insufficient amount of data on transdermal opioids to quantify pain relief. For patients able to maintain on oral or intrathecal opioids for at least 6 months, pain scores were reduced long-term with a 38% mean reduction in pain scores in the intrathecal group and 63.4% mean reduction in pain scores in oral opioid group when treatment lasted 6–18 months. However, there was substantial heterogeneity in the oral studies, which could not be resolved using meta-regression by follow-up time. Further, the summary effect estimate of pain relief from oral opiates was not robust to sensitivity analysis. Consequently, due to lack of robustness upon sensitivity analysis and unexplained heterogeneity, the quantitative estimates of the amount of pain relief associated with opioid therapy may be unstable. Even then,

<table>
<thead>
<tr>
<th>Study/ methods</th>
<th>Participants</th>
<th>Opioids studied</th>
<th>Outcome(s)</th>
<th>Result(s)</th>
<th>Conclusion(s)</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan et al (259)</td>
<td>338 patients were studied with transdermal fentanyl with chronic low back pain</td>
<td>Evaluation of transdermal fentanyl in strong-opioid naïve patients with chronic low back pain</td>
<td>Pain relief, bowel function, quality of life, disease progression, and side effects</td>
<td>Transdermal fentanyl provided significant pain relief</td>
<td>Transdermal fentanyl can safely be used in opioid naïve patients</td>
<td>Most common side effects included constipation, nausea, and vomiting</td>
</tr>
<tr>
<td>Milligan et al (266)</td>
<td>532 pts w/ chronic non-cancer pain studied over 12 months</td>
<td>Transdermal fentanyl compared to previous medication (over 40 different opioids)</td>
<td>Preference of medication, pain control, SF-36, global satisfaction, requirement for breakthrough pain</td>
<td>67% rated pain relief as very good to moderate on transdermal fentanyl, 86% preferred transdermal fentanyl, SF-36 showed improvement for body pain only</td>
<td>Long-term treatment with transdermal fentanyl offered majority of patients at least moderate relief</td>
<td>Nausea 31%; constipation 19%; somnolence 18%; respiratory depression, abuse, or less 1%; withdrawal 3%</td>
</tr>
<tr>
<td>Mystakidou et al (267)</td>
<td>529 patients being treated with oral codeine or oral morphine</td>
<td>Transdermal therapeutic system fentanyl</td>
<td>Quality of Life-Short Form 12</td>
<td>Transdermal therapeutic system-fentanyl significantly improves quality of life within 28 days, and pain management within 48 hours</td>
<td>Transdermal therapeutic system-fentanyl is a safe and effective pain management</td>
<td>Side effects, with constipation (range 4.6%–23.1%) and nausea were the most frequent</td>
</tr>
</tbody>
</table>

long-term opioids were associated with some degree of pain relief. Many patients in the included studies were so dissatisfied with adverse events or insufficient pain relief from opioids that they withdrew from the studies. Even then, for patients able to continue on opioids, evidence (albeit weak) suggested that their pain scores were lower than before therapy began and that this relief would be maintained long-term over 6 months. The data describing long-term safety and efficacy of opioids was insufficient, providing only weak evidence. The evaluations shown for oral opioids (259-265) studied the effectiveness of morphine in 2 studies (259,260), tramadol in one study (261), methadone in one study (262), extended-release oxycodone in one study (263), controlled-release oxycodone in one study (264), and dihydrocodeine, buprenorphine and morphine in one study (265). Thus, overall morphine was studied in 2 studies and all others in one; however, hydrocodone was not studied. Transdermal studies included only fentanyl (259,266,267).

The first systematic review of comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain was published by Chou et al (11), the Oregon Health Resources Commission (OHRC). A total of 16 randomized trials evaluating comparative efficacy and adverse events, enrolling 1,427 patients, and 8 observational studies of adverse events of 1,190 patients were included in this review through October 2002. They were unable to rate any randomized trial as good quality, whereas observational studies were generally of poorer quality than randomized trials. They concluded that there was insufficient evidence to prove that different long-acting opioids are associated with different efficacy or safety profiles. Further, there was also insufficient evidence to determine whether long-acting as a class are more effective or safer than short-acting opioids. They found a subgroup of 3 studies on long-acting versus short-acting oxycodone was more homogenous and provided fair evidence that these formulations were equally effective for pain control (268-270). They included studies with evaluation for as early as 6 days and the longest in randomized trials was 16 weeks. In this study, 2 of the 16 trials compared one long-acting opioid to another one (260,271), one of the trials (271) compared transdermal fentanyl to long-acting morphine, whereas the second trial (260) compared a once daily morphine preparation to a twice daily morphine preparation. Seven trials compared a long-acting opioid to a short-acting opioid (268-270,272-275), and 7 compared a long-acting opioid to a nonopioid or placebo (264,276-281). They identified trials on long-acting oxycodone (264,268-270,281), long-acting morphine (260,271,274,277-279), long-acting dihydrocodeine (273,275), long-acting codeine (272,276,280), and transdermal fentanyl (271). The authors did not identify any trials on methadone, levorphanol, and hydrocodone. The average of enrollment in these trials was 79, which ranged from 12 (278) to 295 (260). Only 3 trials evaluated heterogenous chronic non-cancer pain (271,276,279), whereas 5 trials focused on back pain (269,270,273,274). Two trials focused on neuropathic pain (277,281) and 5 trials focused on osteoarthritis (260,263,268,275,280) with only one study focusing on phantom limb pain (278). All of the trials were of relatively short duration, ranging from 5 days (272) to 16 weeks (274). Thus, these results may not even be applied to chronic pain management settings. Even then, withdrawal rates ranged from 0% to 45%

In a systematic review of opioid treatment for chronic back pain evaluating prevalence, efficacy, and association with addiction, Martell et al (10) evaluated multiple studies through 2005 and concluded that opioids are commonly prescribed for chronic back pain and maybe efficacious for short-term pain relief. However, long-term efficacy of more than 16 weeks was reported to be unclear. They also reported substance use disorders were common in patients taking opioids for back pain, and aberrant medication-taking behaviors occur in up to 24% of cases. Thus, this systematic review also has not provided any long-term evidence for opioid therapy of longer than 6 months.

Kalso et al (12) analyzed available randomized, placebo-controlled trials of the WHO step 3 opioids for efficacy and safety in chronic non-cancer pain through September 2003. Among the 15 randomized placebo-controlled trials they identified, 11 studies with 1,025 patients compared oral opioids with placebo for 4 days to 8 weeks. However, 8 of the 14 included trials had an open-label follow-up, 4 of oral morphine, 3 of oral oxycodone, and 1 of fentanyl (282-289). The mean decrease in pain intensity in most studies was at least 30% with opioids and was comparable in neuropathic and musculoskeletal pain. About 80% of patients experienced at least one adverse event with constipation (41%), nausea (32%), and somnolence (29%) being most common. Only 44% of the 388 patients on open-label treatment were still on opioids after therapy for between 7 and 24 months. They concluded that the short-term efficacy of opioids was good in both neuro-
pathic and musculoskeletal pain conditions, whereas, only a minority of patients in these studies were onto long-term management with opioids, precluding any conclusion with regards to effectiveness on a long-term basis. Overall, they concluded that the mean relief with opioid was about 30%. The lowest maximum doses, morphine 30 mg and oxycodone 20 mg daily were used in musculoskeletal pain and were not effective. Only 3 of the 8 studies found improvement in function or disability.

Furlan et al (13) also performed a meta-analysis of effectiveness and side effects of opioids with the inclusion of 41 randomized trials involving 6,019 patients with 80% of the patients suffering with nociceptive pain of osteoarthritis, rheumatoid arthritis, or back pain; 12% with neuropathic pain of post herpetic neuralgia, diabetic neuropathy, or phantom limb pain; 7% fibromyalgia; and 1% with mixed pain. They reported methodological quality of 87% of the studies as high. They also classified opioids as weak, which included tramadol, propoxyphene, and codeine or strong, which included morphine and oxycodone. However, hydrocodone was not included in either category. In this meta-analysis, they found that dropout rates averaged 33% in the opioid groups and 38% in the placebo group with average duration of treatment of 5 weeks, ranging from 1 to 16 weeks.

Ballantyne (6) and Ballantyne and Mao (14) performed a review of opioid therapy for chronic pain. In their review, they included 8 studies evaluating for 4 weeks or less, 7 studies for 12 weeks or less, and only 2 studies evaluated for a period of 14 weeks or longer with the longest duration being 24 weeks. They concluded that the only knowledge of long-term analgesic efficacy comes from surveys, case series, open-label follow-up studies in association with some RCTs, and epidemiological studies. Further, they concluded that surprisingly, only a few of the existing opioid studies have focused on function and quality of life.

Sandoval et al (18) performed a systematic review of methadone involving 21 papers with 545 patients with multiple non-cancer pain conditions. The methadone starting dose ranged from 0.2 mg to 80 mg per day with maximum doses of 20 mg to 930 mg per day. They reported statistical improvement in pain for methadone with 20 mg per day compared to placebo in 59% of the cases, side effects in 225 patients with nausea and/or vomiting in 23%, sedation in 18%, itching and/or rash in 13%, and constipation in 11%. The results of oral methadone for chronic non-cancer pain are illustrated in Table 15 (18,290-294).

Cepeda et al (17) performed a systematic review and meta-analysis of 11 RCTs to determine the analgesic effectiveness, effect on physical function, the duration of benefit and safety of oral tramadol in patients with osteoarthritis. The study only included RCTs that evaluated the effect of tramadol or tramadol plus acetaminophen on pain levels in patients with opioid addiction (OA). Studies that evaluated other types of arthritis (e.g., rheumatoid arthritis), non-osteoarthritic joint pain, or back pain were excluded. The study concluded that tramadol is more effective than placebo for the treatment of OA when pain is moderate. However, when OA pain is severe, there is only a small benefit to the patient. The study also notes that tramadol tolerability is increased when a slow titration regimen is implemented (e.g. 100 mg/day for 7–10 days, then 200 mg/day). The study found this approach halves the proportion of people who interrupt therapy because of adverse events. Since only 2 studies evaluated tramadol for more than 8 weeks, the authors were unable to determine whether the clinical effectiveness of tramadol decreases with chronic use. Finally, another noted limitation was that only one of the 11 systematic reviews included in this study was not industry funded. Thus, it is possible for an overestimation of treatment effects of tramadol in patients with osteoarthritis.

Eisenberg et al (15) in a systematic review of opioids for neuropathic pain included 23 trials with 267 patients for short-term and 460 patients for intermediate term defining short-term as less than 8 days and intermediate term as 8 days to 10 weeks. They evaluated short-term trials of morphine, alfentanil, fentanyl, meperidine, and codeine, whereas, intermediate trial studies included morphine, oxycodone, methadone, and levorphanol. They reported mixed results with short-term trials of less than 8 days, whereas intermediate trials of 8 days to 10 weeks showing consistent opioid analgesic efficacy. They also reported nausea in 33%, constipation in 33%, drowsiness in 29%, dizziness in 21%, and vomiting in 15% with withdrawals in 11% of the patients.

Based on the information available from an extensive review of the literature, it appears that it is necessary to utilize less rigorous forms of evidence to evaluate long-term effectiveness, since it is not feasible to conduct RCTs over prolonged periods. Even in the open studies of long-term effectiveness, as many as 56% of patients abandon the treatment because
**Table 15. Characteristics of case series evaluating the effectiveness of methadone over 6 months.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Effectiveness (no. Patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robbins (290)</td>
<td>66 patients (53 F, 13 M), ages 26 to 58 y/o, with chronic headaches. Indication for methadone was ineffective pain relief with previous treatments: NSAIDs, calcium channel blockers, beta-blockers, valproate, and antidepressants</td>
<td>Average dose was 10 mg/day. Co-interventions: not described. Time: 6 months Side effects: fatigue, confusion, nausea, constipation, profuse sweating, lightheadedness, and rash</td>
<td>Pain relief scale: 1-25% = no relief: 27 patients (41%) 25-50% = mild relief*: 5 patients (8%) 50–75% = moderate relief: 16 patients (24%) 75-100% = excellent relief: 18 patients (27%)</td>
<td>Meaningful = 34 Non-meaningful = 32 Unclassifiable = 0</td>
</tr>
<tr>
<td>Robbins (291)</td>
<td>148 patients. Only 42 remained on methadone after 6-mos period (33 F, 9 M). With chronic daily headache refractory to standard therapies such as NSAIDs, calcium channel blockers, divalproex, antidepressants, and methysergide</td>
<td>Average dose was 10 mg/day. Co-interventions: not described. Time: 6 months Complications and side effects: not described</td>
<td>42 reported moderate or excellent relief. Quality of work and home life in these 42 patients: 86% of patients had improvement in work performance; 71% improvement in relationship with partner; 81% improvement in relationship with children and friends; 60% improvement in sexuality</td>
<td>Meaningful = 42 Non-meaningful = 106 Unclassifiable = 0</td>
</tr>
<tr>
<td>Mironer et al (292)</td>
<td>47 patients (18 F, 29 M), 57 y/o on average (from 29 to 88), with neuropathic pain. Indication for methadone was ineffectiveness with previous treatments: opioids, anticonvulsants, antidepressants, calcium channel blockers, intravenous and oral lidocaine, etc.</td>
<td>Average daily intake of methadone was 27 mg/day (range 10-60 mg/day) The most common co-intervention: gabapentin (12 patients). Duration of treatment varied from 6 to 37 months</td>
<td>Patients reported on average 30% to 90% pain relief, with 34 out of 47 having more than 50% improvement in their pain scores. Side effects: not significant</td>
<td>Meaningful = 47 Non-meaningful = 0 Unclassifiable = 0</td>
</tr>
<tr>
<td>Quang-Cantagrel et al (293)</td>
<td>Methadone was given to 29 patients out of 86 (50 F, 36 M) with various non-cancer pain syndromes (back pain neuropathy; joint pain, visceral pain, reflex sympathetic dystrophy, headache, and fibromyalgia). Indication for methadone was ineffectiveness with previous treatments</td>
<td>Doses of methadone were 39.0 6 17.0 mg/day. Co-interventions: not described. Duration of the treatment was an average of 49.4 wks</td>
<td>There was 1 case of addiction and no case of tolerance Complications and side effects (52%) included: nausea, vomiting, sedation, itching, and kidney alterations</td>
<td>Meaningful = 8 Non-meaningful = 21 Unclassifiable = 0</td>
</tr>
<tr>
<td>Moulin et al (294)</td>
<td>50 patients (22 F, 28 M) with mean age of 52.7 and a variety of intractable neuropathic pains. The indications were ineffectiveness of previous medications and side effects</td>
<td>Initial dose of 20 mg/day. Maximum dose 160 mg/day Maintenance dose 121 mg/day. Co-interventions: tricyclic antidepressants, NSAIDs, SSRI, benzodiazepines, and anticonvulsants. Mean duration of treatment: 17.3 months</td>
<td>26 (52%) improved with methadone: 3 mild, 16 moderate, 6 marked, and 1 complete pain relief 16 patients (32%) reported improvement in function Complications and side effects: not described</td>
<td>Meaningful = 23 Non-meaningful = 27 Unclassifiable = 0</td>
</tr>
</tbody>
</table>

of lack of efficacy or side effects (9,12). In addition, it has been described that many opioid trials utilize enrichment in their protocols with removal of patients who do not respond, also known as selecting out during the pre-trial phase with an additional unusually high drop-out rate across opioid trials during enrichment, compromising the internal validity of these trials (6,295). Further, functional status improvement has been studied meagerly and the results have been poor.

6.2.1 Effectiveness of Individual Drugs

In the United States, the most commonly used therapeutic opioids in the order of maximum use are as follows: oxycodone, hydrocodone, codeine, morphine, and methadone. Transdermal fentanyl is the least used opioid behind meperidine and hydromorphone. However, the available evidence is better for sustained-release morphine and transdermal fentanyl, compared to all other drugs, though weak.

Morphine

Allan et al (259) evaluated sustained release oral morphine in 342 strong-opioid naïve patients with chronic low back pain with assessment of pain relief, quality of life, disease progression, and side effects, including bowel function. Sustained release morphine provided significant improvement of mean VAS scores for patients who remained in the study for 56 weeks. However, use of concomitant, strong, short-acting opioids was frequent in 50% of the patients as rescue medication. While quality of life scores showed improvement in physical health, there was no significant difference with mental health. They concluded that strong opioids may be indicated for chronic low back pain that is not relieved by other forms of analgesia.

Caldwell et al (260), in an open-label extension trial evaluated Avinza® an extended-release morphine formulation, in 181 patients during the 26-week open-label extension trial. Significant reductions in pain intensity and improved sleep measures were observed. However, improvements were not observed in physical function. Twenty-eight or 15% of patients were excluded entirely from the subset analysis due to concomitant therapy with NSAIDs and/or acetaminophen use. Constipation and nausea were the most frequent adverse effects reported in over 80% of the patients.

Zenz et al (265) evaluated long-term oral opioid therapy in 100 patients with chronic non-cancer pain, utilizing either sustained-release morphine, dihydrocodeine, or buprenorphine, with 23 patients in the morphine group. Good pain relief was obtained in 51 patients, partial pain relief was reported by 28 patients, and 21 patients reported no beneficial effect from opioid therapy. The most common side effects were constipation and nausea.

Maier et al (296) evaluated long-term efficacy of morphine in 121 patients with chronic non-cancer pain, 5 years after the onset of medical treatment. Frequency of withdrawal was 14.8% mainly due to lack of efficacy with an average treatment time of 66 months (37–105 months with 87% more than 5 years). The study showed that patients with long-term opioid intake exhibited significantly lower pain intensity and higher contentment with the pain management and improvement in physical status and quality of life. There were inconsistent changes in opioid dosages over the period of 5 years, without any change in 33% of the patients, with decrease in 16%, slight increase in 27%, and high increase in 19%. The survey demonstrated a very low frequency of withdrawal in patients with long-term opioid medication after initial response without evidence for tolerance development, especially if their treatment was controlled in a pain center.

Tassian et al (297) evaluated the long-term effects of sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Of the 28 patients initially included in the study, 18 patients received oral sustained morphine on a long-term basis with significant improvement in pain, function, and mood. Morphine induced persisting effects on pain, and to a lesser extent on quality of life and mood at 12 months, with no disruption of cognitive function.

Table 13 illustrates results of multiple studies evaluating the long-term effectiveness of morphine.

Transdermal Fentanyl

Allan et al (259) evaluated 338 patients with chronic low back pain with transdermal fentanyl for a period of 13 months. The proportion of patients experiencing a 50% or greater improvement in back pain was observed to be 40% in the patients with rest, 47% on movement and during the day, and 53% in patients at night. Concomitant medication with possible analgesic effect and rescue medication during the trial was seen in greater than 80% of the patients with 52% using strong opioids.

Milligan et al (266) evaluated long-term efficacy and safety of transdermal fentanyl in the treatment of chronic non-cancer pain in an international, multicenter, open-label trial over a period of 12 months,
with completion of the trial by 301 (57%) of the patients. An average of 67% of patients within the efficacy analysis group (n=524) reported very good, good, or moderate pain control, with global satisfaction reported in 42% of the patients. The majority (86%) of patients reported a preference for transdermal fentanyl over their previous treatment. There was significant improvement in the bodily pain scores of Short Form 36. The most frequent treatment-related adverse events were nausea (31%), constipation (19%), and somnolence (18%).

Mystakidou et al (267) evaluated the effectiveness of transdermal fentanyl in the long-term management of non-cancer pain, in 529 patients in a prospective open-label study. The mean duration of therapy for effective pain management was 10 months, and 90% of patients sustained effectiveness with improvement in quality of life scores and pain. Further, the improvements were not influenced by pain type or etiology.

Table 14 illustrates the results of studies evaluating long-term effectiveness of transdermal fentanyl.

**Oxycodone**

The effectiveness of oxycodone was evaluated in multiple studies (286,298-300).

Portenoy et al (300) looked at sustained release oxycodone use over a 3-year period in 233 non-cancer patients who had participated earlier in clinical trials regarding the same medication. At study's end, pain was the same or improved in 70% to 80% of the patients. They noted that approximately 50% of the patients stopped the opioids due to side effects in the first 6 months. Adverse effects were seen in 88% of the patients on sustained release oxycodone.

Rauck et al (298), in a randomized, open-label, multicenter trial, studied the effectiveness of sustained release oxycodone comparing it with sustained release morphine in 266 patients up to 8 months. Both groups showed significant improvement. The concluded that compared to twice daily sustained release oxycodone, once daily sustained release morphine resulted in significantly better physical function and quality of life.

Roth et al (264) studied 133 patients with osteoarthritis with follow-up lasting up to 6 months. Fifty-eight patients completed 6 months of treatment and 41 completed 12 months of follow-up, whereas 15 completed 18-month follow-up. They concluded that sustained release oxycodone provided sustained analgesia.

Hermos et al (299) in an observational review reported the results of 47,000 veterans receiving opioids through the VA system of which 2,200 received oxycodone for over 9 months however, 31% of these patients were diagnosed with cancer with mean daily doses of 3.9 tablets per day with a range of 0.5 to 13 with minimum change over time. Table 16 illustrates the results of studies evaluating oxycodone.

**Hydrocodone**

There were no studies evaluating the effectiveness of hydrocodone even though this is the most commonly used drug.

**Methadone**

Fredheim et al (262) studied 8 chronic non-cancer patients experiencing insufficient pain control or intolerable side effects during treatment with oral morphine who switched to oral methadone. They showed that opioid switching from low doses of oral morphine to an equi-analgesic oral methadone causes a small but statistically significant increase in QTc time.

Fredheim et al (301) showed that, after switching 12 patients from morphine to methadone, their blood levels and metabolite levels remained steady for the 9-month study period, contradicting the hypothesis of metabolic tolerance and auto-induction of hepatic enzymes during long-term methadone therapy. However, they noted that the oral dose had a poor correlation with serum blood levels, confirming a large inter-individual variability of metabolism.

Sandoval et al (18), in a systematic review of oral methadone for chronic non-cancer pain described the effectiveness of methadone in multiple observational studies as shown in Table 15.

**Tramadol**

Cepeda et al (17) performed a systematic review and meta-analysis of multiple randomized trials.

Controlled-release tramadol was evaluated by Beaulieu et al (302) in a multi-center, randomized, double blind, double dummy, 8-week crossover study, comparing it to immediate release tramadol. Overall pain scores were significantly better with the controlled release formulation. Since tramadol has a serotonin and norepinephrine reuptake inhibition action, continuous dosing (such as seen with extended release formulations) would be expected to be more effective than intermittent dosing (since the intermediate dosing does not allow for accumulation of serotonin and norepinephrine).

Adams et al (303), in a study funded by Ortho-McNeil, performed a double blind, 12-month crossover trial, looking at 3 different treatment arms: tramadol alone, tramadol randomized against
Table 16. Results of studies evaluating long-term effectiveness of oxycodone.

<table>
<thead>
<tr>
<th>Study/ methods</th>
<th>Participants</th>
<th>Opioids studied</th>
<th>Outcome(s)</th>
<th>Result(s)</th>
<th>Conclusion(s)</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rauck et al (298)</td>
<td>Chronic, severe low back pain (n=266) Sustained release morphine vs. sustained release oxycodone Up to 8 months</td>
<td>Randomized to sustained release morphine (Avinza) or sustained release oxycodone (Oxycontin) period of dose titration, then 8 week evaluation and optional 4 month extension (n=174)</td>
<td>Short Form-12, Work Limitation Questionnaire</td>
<td>Improvements seen in both groups (&gt; in sustained release morphine)</td>
<td>Compared to twice a day sustained release oxycodone, once daily sustained release morphine resulted in significantly better physical function and quality of life activities.</td>
<td>None described</td>
</tr>
<tr>
<td>Roth et al (264)</td>
<td>133 patients with osteoarthritis 6 to 12 months 58 patients completed 6 months treatments, 41 completed 12 months, 15 completed 18 months</td>
<td>Sustained release oxycodone bid 10 mg (n=44) 20 mg (n=44) vs placebo (n=45)</td>
<td>VAS, mood, sleep, quality of life</td>
<td>Mood and quality of life improved. Analgesia was maintained and dose was stable</td>
<td>Sustained release oxycodone provided sustained analgesia</td>
<td>Typical opioid side effects were noted and decreased over time</td>
</tr>
<tr>
<td>Hermos et al (299)</td>
<td>47,000 veterans receiving opioids through the VA system</td>
<td>Oxycodone with APAP; concurrent use of long acting narcotics, benzodiazepines, tricyclic antidepressants, and anti-epileptic drugs</td>
<td>Number of doses</td>
<td>About 2,200 received oxycodone with APAP for &gt; 9 months (31% with diagnosis of cancer); mean daily dose 3.9 tabs/day (0.5-13.0) with minimal change over time</td>
<td>Among patients without cancer, patients with concurrent benzodiazepines, psychogenic pain, alcohol abuse, and HIV/AIDS had more prescription management problems</td>
<td>None described</td>
</tr>
<tr>
<td>Portenoy et al (300)</td>
<td>233 patients non-cancer pain Low back pain (68 patients) Neuropathic (67 patients) Osteoarthritis (84 patients)</td>
<td>Sustained release oxycodone 1 yr (141 pts) 2 yrs (86 pts) 3 yrs (39 pts)</td>
<td>Brief Pain Inventory Short Form, VAS, med acceptability, adverse events, aberrant drug behavior (abuse, misuse, withdrawal)</td>
<td>Brief Pain Inventory Short Form scores decreased after starting oxycodone. Pain scores improved in approximately 70 to 80% thru month 33 and 54% at month 36.</td>
<td>There need to be more data regarding efficacy of long-term opioids</td>
<td>Adverse events seen in 88% sustained release oxycodone. Constipation (15%), nausea (12%), somnolence (8%), vomiting (7%), depression (2%). 7 patients died, presumably not related to medication.</td>
</tr>
</tbody>
</table>

NSAIDs, and tramadol randomized against hydrocodone. They looked at pain scores, SF-36, and what they called an “abuse index.” They found that the prevalence of abuse/dependence over the 12-month period was equal for the tramadol and NSAIDs, but, as expected, the hydrocodone had twice as much abuse.

Table 17 illustrates results of studies of tramadol.

<table>
<thead>
<tr>
<th>Study/methods</th>
<th>Participants</th>
<th>Opioids studied</th>
<th>Outcome(s)</th>
<th>Result(s)</th>
<th>Conclusion(s)</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harati et al (261)</td>
<td>117 with painful diabetic neuropathy</td>
<td>Tramadol</td>
<td>Self-administered pain intensity scores (scale 0-4; none to extreme pain) and pain relief scores (scale -1-4; worse to complete relief)</td>
<td>Tramadol reduced mean pain scores which were maintained throughout the study</td>
<td>Tramadol provides long-term relief of the pain of diabetic neuropathy</td>
<td>The most common adverse events were constipation, nausea, and headache</td>
</tr>
<tr>
<td>Adams et al (213)</td>
<td>A total of 11,352 subjects were enrolled</td>
<td>NSAIDs, tramadol, hydrocodone</td>
<td>Abuse</td>
<td>Tramadol was effective with less abuse potential than hydrocodone</td>
<td>These results support the hypothesis that the rate of abuse identified with tramadol is less than the rate associated with hydrocodone</td>
<td>None described</td>
</tr>
<tr>
<td>Beaulieu et al (302)</td>
<td>Chronic non cancer pain patients: (n=122)</td>
<td>Pts randomized to 2 groups: active tramadol controlled-release + placebo 4-6 hours prn or placebo plus active tramadol immediate-release 4-6 hours prn for 4 weeks and then switched to alternate treatment for another 4 weeks</td>
<td>Pain intensity; pain disability index; sleep quality and quantity; analgesic effectiveness; adverse events at each visit</td>
<td>Overall pain intensity scores significantly better with controlled-release tramadol. No differences in total pain disability index, or overall pain and sleep scores</td>
<td>Significantly better pain control in chronic benign pain with tramadol controlled-release every 24 hours vs. Tramadol immediate-release every 4-6 hours prn</td>
<td>3 patients experienced serious adverse events. The only difference in adverse events was nausea seen more often in the tramadol controlled-release (p&lt;0.021). 2 patients hospitalized with vomiting from the immediate-release group; one hospitalized for asthenia in the controlled-release group</td>
</tr>
</tbody>
</table>

Oxymorphone

Rauck et al (304) studied oxymorphone in an open-label 6-month study looking at efficacy and side effects. They reported 75% of patients could be stabilized on a dose of oxymorphone that provided effective pain relief with tolerable side effects.

McIlwain and Ahdieh (263), in a 52-week, multicenter open-label extension study of 153 patients with moderate to severe chronic osteoarthritis-related pain, showed improvement in pain. They found that oxymorphone ER provides a new 12-hour analgesic for the treatment of moderate to severe, chronic osteoarthritis-related pain in patients who may require long-term opioid therapy.

6.3 Summary of Evidence

Based on the review of multiple systematic reviews and the available literature, the evidence for the effectiveness of long-term opioids in reducing pain and improving the functional status for 6 months or longer is variable. The evidence for transdermal fentanyl and sustained-release morphine is Level II-2 based on the quality of evidence criteria described by the U.S. Preventive Services Task Force as illustrated in Table 1 (26). For oxycodone, the level of evidence is II-3, however, for hydrocodone and methadone, the level of evidence is III.

6.4 Recommendation

Based on the review of multiple systematic reviews and the available literature, the recommendation is 2A — weak recommendation, high-quality evidence with benefits closely balanced with risks and burden; derived from RCTs without important limitations or overwhelming evidence from observational studies; with the implication that with a weak recommendation, best action may differ depending on circumstances or patients’ or societal values.

7.0 Adherence Monitoring

7.1 Introduction

Important issues in opioid therapy in chronic pain revolve around appropriate use of prescription opioids. Patients that describe symptoms of pain, and lack of relief, are one of the most common patient populations in the primary care community. Perceived interference of activities of daily living creates the perception of a need of drugs, and sometimes these patients are divulging signs and symptoms that may threaten the patient-physician relationship that is built on trust. The primary care physician is ill equipped to handle these patients, they rapidly lose control, and then they often are referred to the pain management physician as a “risk shift.” These patients expect something to be done, and are often promised that the pain clinic will maintain the same level of care. It is the pain physician’s responsibility to define their personal risk tolerance. Many times the primary care physician will not engage in opioid agreements and not fully explore non-narcotic medication alternatives. Adherence monitoring is crucial to avoid abuse of the drugs and at the same time to encourage appropriate use, and involves the initiation of drug screening, pill counts, and patient care agreements, with the motto of “trust but verify.”

A high-risk practice, such as a pain management practice, will readily activate an adherence monitoring program, utilize advanced documentation, have a strong office policy, a threshold policy, and will define how many patients of this nature will be treated in the practice. If available, a second opinion from an addictionologist or psychologist may be advised, and a high-risk practice should understand that these charts should be readily available for the Board of Medical Examiners to review for legitimate need. Frequent functional assessments are mandatory. The risk environment is increased with Medicaid and disabled patients, patients with a previous history of substance abuse, and psychiatric disorders, particularly bipolar personalities, borderline personalities, history of alcohol abuse, and chaotic home environment. Boundary violations, which unfortunately do occur in this patient population, are never acceptable, and a difficult patient is best chaperoned at each visit.

The high-risk patient may have an abnormal pill count or drug screen. The patient that is discharged from a previous practice will have a documented historical reason, and records from this previous practice are recommended. High risk includes discharge from a previous practice, chaotic lifestyle, recent arrival to the area, poor response to multimodality approach to pain, sedentary lifestyle, cigarette smoker, and possibly obesity. Also patients that are litigating, disabled, and on Medicaid may also be at higher risk and may require more adherence monitoring. Patients should be expected to take a proactive role in their own healthcare. The risk/reward of the relationship is constantly reassessed. The patient should understand that pills kill, pain does not. The concept of legitimate
Confusion surrounding a specific operational definition of opioid misuse among chronic pain patients has complicated the process of effectively assessing and predicting its occurrence (159). The typical elements of drug diversion involve theft, forgery, counterfeit prescriptions, fraud imposed against physician/pharmacy for other patients, and promoting pill mills (1-4).

There is a need for better tamper-proof opioids. As long as long-acting opioids can be easily converted into a rapidly absorbed form, there will be a effort to divert these medications for illicit use.

7.2 Screening for Opioid Abuse

The decision to use opioids for chronic pain patients, like all medical decisions, is based on a balance between risk and potential benefit. Screening for opioid misuse and abuse is an exercise to strengthen the patient-physician relationship. This should not be confrontational, and the patient has to understand that this is like any other lab test. A physician would respond to abnormal liver functions or anemia, just as a pain physician responds to a screening questionnaire, urine drug screen, or pill count.

Even though several investigators have described multiple screening instruments in detecting opioid abuse or misuse in chronic pain patients, there is no widely used screening instrument in the current practice. Most look at problematic behaviors such as focusing on opioids, escalation of opioid use, multiple phone calls and visits, lack of improvement with increased medications, multiple prescription problems (lost or stolen scripts), and opioids from multiple providers (159).

7.3 Urine Drug Testing (UDT)

Although drug testing may be performed by testing the urine, serum, or hair, urine is considered as the best biologic specimen for detecting the presence or absence of certain drugs due to specificity, sensitivity, ease of administration, and the cost. However, controversies exist regarding the clinical value of UDT, partly because most current methods were designed for, or adapted from, forensic or occupational deterrent-based testing for illicit drug use and are not necessarily optimized for clinical applications in chronic pain management. In chronic pain management, UDT should be used with an appropriate level of understanding (which can improve a physician’s professional ability to manage therapeutic prescription drugs with controlled substance), and to diagnose substance abuse or appropriate intake of drugs, thereby leading to proper treatment. They should be random, well organized, and synchronized with a well-understood testing lab. The lab understands you, and you understand what they are testing. False-positives, negatives, and the scope of testing should also be understood.

It is also critical to understand the metabolism of opioids, to avoid falsely accusing patients of abuse. For instance, codeine is metabolized to morphine, and hydrocodone to hydromorphone. However, it has only been recognized recently that morphine (in high doses) can be metabolized to hydromorphone (305). The hydromorphone is usually about 2% of the morphine dose (which can be determined by quantitative testing), and is usually seen in patients taking at least 100 to 200 mg morphine per day. In a retrospective case-control study (306), 66% of patients on morphine showed evidence of hydromorphone in the UDT; this was seen more commonly in females, despite the fact that the females were taking lower doses of morphine.

In principle, UDTs can detect the parent drug and/or its metabolite(s) and, therefore, demonstrate recent use of prescription medications and illegal substances. For most clinical applications, initial testing is done with class-specific immunoassay drug panels, which typically do not identify individual drugs within a class. However, this may, and perhaps should, be followed by a more specific technique such as a gas chromatography/mass spectrometry (GC/MS) to identify or confirm the presence or absence of a specific drug and/or its metabolite(s). Numerous differences between various tests and even among the laboratories and manufacturers of various rapid drug screen tests include the number of drugs tested, cross-reactivity patterns, cut-off concentrations, and drug interferences. Clinicians should remember that the cut-off concentrations used for drugs in federally regulated testing, particularly opioids, are too high to be of value in clinical practice. Federally regulated testing includes 5 drugs or drug classes that are tested for in federal employees and federally regulated industries, including marijuana, cocaine, opiates, PCP, and amphetamines/methamphetamines, with pre-determined cut-off levels with mandatory reconfirmation with the results by GC/MS, along with split sample in chain of custody requirements. In contrast, nonregulated testing is used for many purposes, including monitoring pain patients clinically.
In clinical practice, UDT is used for accurate record keeping, to identify use of undisclosed substances, to uncover diversion or trafficking, and to determine appropriate intake of prescribed substances. There are typically 2 types of UDT. These approaches used in proper combination can reduce cost, ensure accuracy, and improve efficiency. The 2 main types of UDT methods are:

1) Immunoassay drug testing, either laboratory based or by rapid drug testing (“site of service”).
2) Laboratory-based specific drug identification with GC/MS, high-performance liquid chromatography (HPLC), etc.

Immunoassays, which are based on the principle of competitive binding, use antibodies to detect the presence of a particular drug or metabolite in a urine sample. Immunoassay drug testing is provided either in the laboratory or by means of rapid drug testing at the point of service. An immunoassay’s ability to detect drugs will vary according to the drug concentration in the urine and the assay’s cut-off concentration. Any response above the cut-off is deemed positive and any response below the cutoff is negative. Further, immunoassays are subject to cross-reactivity. For example, tests for cocaine are highly predictive of cocaine use. In contrast, tests for amphetamine/methamphetamine are highly cross-reactive and unreliable. They may detect other sympathomimetic amines such as ephedrine and pseudoephedrine and, therefore, are not very predictive for amphetamine/methamphetamine use. Further, standard tests for opiates are very responsive for morphine and codeine (but do not distinguish the difference), but show a lower sensitivity for semisynthetic/synthetic opioids such as oxycodone, fentanyl, methadone, and buprenorphine, such that a negative response does not exclude use of these opioids. Specific immunoassay tests for semisynthetic/synthetic opioids are available.

Table 18 illustrates cut-off levels for various drugs detected by urine analysis. Ideally, a panel in chronic pain management settings for rapid drug screening should include not only opiates, but also oxycodone and methadone. In addition, the panel should include cocaine, marijuana, amphetamines and methamphetamine for illicit drugs and benzodiazepines and barbiturates for other controlled substances. If

<table>
<thead>
<tr>
<th>Drug</th>
<th>Screening cutoff concentrations ng/mL urine</th>
<th>Analyte tested in confirmation</th>
<th>Confirmation cutoff concentrations ng/mL (non-regulated)</th>
<th>Confirmation cutoff concentrations ng/mL (federally regulated)</th>
<th>Urine detection time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine</td>
<td>1,000</td>
<td>Amphetamine</td>
<td>500</td>
<td>1,000</td>
<td>2-4 days</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>200</td>
<td>Amobarbital, secobarbital, other barbiturates</td>
<td>200</td>
<td>300</td>
<td>2-4 days for short acting; up to 30 days for long acting</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>200</td>
<td>Oxazepam, diazepam, other benzodiazepines</td>
<td>200</td>
<td>300</td>
<td>Up to 30 days</td>
</tr>
<tr>
<td>Cocaine</td>
<td>300</td>
<td>Benzoylecgonine</td>
<td>150</td>
<td>300</td>
<td>1-3 days</td>
</tr>
<tr>
<td>Codeine</td>
<td>300</td>
<td>Codeine, morphine</td>
<td>300; 300</td>
<td>2,000; 300</td>
<td>1-3 days</td>
</tr>
<tr>
<td>Heroin</td>
<td>300</td>
<td>Morphine, 6-acetylmorphine</td>
<td>300; 10</td>
<td>2,000; 300</td>
<td>1-3 days</td>
</tr>
<tr>
<td>Marijuana</td>
<td>100; 50; 20</td>
<td>Tetrahydrocannabinol</td>
<td>15</td>
<td>50</td>
<td>1-3 days for casual use; up to 30 days for chronic use</td>
</tr>
<tr>
<td>Methadone</td>
<td>300</td>
<td>Methadone</td>
<td>300</td>
<td>300</td>
<td>2-4 days</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>1000</td>
<td>Methamphetamine, amphetamine</td>
<td>500; 200</td>
<td>1,000; 50</td>
<td>2-4 days</td>
</tr>
<tr>
<td>Phencyclidine</td>
<td>25</td>
<td>Phencyclidine</td>
<td>25</td>
<td>25</td>
<td>2-7 days for casual use; up to 30 days for chronic use</td>
</tr>
</tbody>
</table>
a custom panel is not available, multiple tests may have to be performed as rapid drug screening.

Cross-reactants with cannabinoids include Orudis KT, Aleve, Sustiva, Protonix, Marinol, ibuprofen, promethazine, and riboflavin. Opioid cross-reactivity includes poppy seeds, chlorpromazine, rifampin, dextromethorphan, and quinine. Cross-reactants to amphetamines include ephedrine, methylphenidate, pseudoephedrine, trazodone, desipramine, bupropion, fenfluramine, propranolol, labetalol, mexiletine, selegiline, tyramine, amantadine, ranitidine, phenylephrine, and Vicks Vapor Spray. PCP cross-reactants include chlorpromazine, thioridazine, dextromethorphan, diphenhydramine (Benadryl), and venlafaxine (Effexor). Benzodiazepine cross-reactants include oxaprozin (Daypro) and sertraline (Zoloft) and some herbal agents, while opioid cross-reactants include ofloxacin (Floxin), papaverine, and rifampin, as well as the oft-described poppy seeds. ETOH cross-reactants sometimes include asthma inhalers. Since false-negatives and false-positives are possible, when questions arise, prior to taking any actions, a confirmatory test or no threshold test must be performed in the laboratory.

Urine is sometimes adulterated. Collected within 4 minutes, the temperature range should be between 90° and 100° F. The pH should be between 4.5 and 8, and creatinine norm is 20 mg/dl and up. Dilute urine creatinine is <20 mg/dl and adulterated urine is <5 mg/dl. Urine testing has difficulty identifying LSD, hallucinogens, inhalants, and anabolic steroids. A new emerging therapy for fibromyalgia, flu nitrazepam (Rohypnol), is the “date-rape” drug that is utilized sometimes for sleep; it may show up on urine screening as a benzodiazepine. Urine can be adulterated with glutaraldehyde detergent, potassium nitrate acid, and Pyridium chlorochromate, which are readily available over the internet.

Physicians may establish zero or low tolerance, but this should be discussed with the patient on the initial visit, and should be part of the written clinic policy. This may include referral to an addictionologist or psychologist, or may result in the refusal to prescribe opioids. However, it usually does not warrant dismissal of the patient. The practice limits for presence of cocaine and marijuana may range from only one positive screen (zero tolerance) to 3 positive screens and appropriate action later. Improper use of prescription drugs and doctor shopping should be dealt in the same manner.

7.4 Periodic Review and Monitoring
7.4.1 Periodic Review

Periodic reviews should assess the medical diagnosis, psychological diagnosis, informed consent, treatment agreement, appropriate opioid therapy with or without adjuvant medications or with or without interventional techniques, pre- and post-intervention assessment of pain level, and function and reassessment of pain score and level of function.

Regular assessment of the patient along with periodic review of the diagnosis is extremely important. Routine assessment of the “4 As” (analgesia, activity, aberrant behavior and adverse effects) will help to direct therapy and support pharmacologic actions taken (PASSIK reference add here). Further assessment should be performed by periodic monitoring, pill counts, and UDT (see below).

7.4.2 Periodic Monitoring

At reasonable intervals depending on specific circumstances of a given patient, the physician should review the course of treatment and any new information about the etiology of the pain. Continuation or modification of therapy should depend on the physician’s evaluation of progress towards the stated treatment goals, such as a reduction in a patient’s pain scores and improved physical and/or psychosocial function (i.e., ability to work, utilization of healthcare resources, activities of daily living, and quality of social life). If treatment goals are not being achieved despite medication adjustments, the physician should reevaluate the appropriateness of continued treatment with the current medications. The physician should monitor patient compliance in medication usage and related treatment plans.

Some physicians have long embraced long-term opioid therapy, sometimes naïve of the consequences. Even the term pseudoaddiction involved only one case and one patient, and from there evolved into the philosophy of pseudoaddiction which took on its own meaning: “I think, therefore it is.” Patients are becoming more demanding and the question is raised whether the detection of aberrant use is contradictory to the physician’s goal, which is developing a sacred relationship.

7.4.3 Prescription Drug Monitoring

Prescription drug monitoring programs collect information to assist state law enforcement and regulatory agents in identifying and investigating illegal practices related to controlled substances. However, some of the existing prescription programs and the
recently passed NASPER should also assist physicians and pharmacists in identifying controlled substance abuse. The purpose of NASPER is to ensure access to care, delegate the appropriate use of opioids to those in the most need, and identify potential abusers that misuse, divert, or doctor shop.

7.4.4 Periodic Education

Drug education for the physicians, providers, and patients is crucial. While it appears that certain medications have revolutionized the treatment of chronic pain in the United States, physicians must balance the medical need with the possibility of abuse and diversion, as well as the necessity to comply with the state and federal regulations. It is obvious that healthcare practitioners are not only expected to prescribe medications when there is medical need and document appropriately, but also they are expected to prevent illegal diversion and identify drug abuse. Consequently, education is a critical component of any program to control the diversion of prescription drugs.

7.4.5 Pill Counts

Random pill counts, along with UDT and prescription monitoring, would greatly reduce controlled substance abuse. Pill counts are essential in patients with suspicion of abuse. However, these can also be performed randomly on high-risk patients.

A pill count is performed by notifying the patient a day before or on the day of the appointment of the patient, requesting the patient to bring with them their unused pills. The inability to provide pills or providing a reduced number will indicate use beyond the prescription. Pill counts above the expected ranges would indicate inappropriate low intake (suggesting that the medications are being over-prescribed). Recently, it has been reported that some unsuspected elderly patients may be selling controlled substances to supplement their income.

8.0 Principles of Opioid Usage

8.1 Introduction

In interventional pain management, patients may receive not only opioid analgesics, but also other controlled or non-controlled drugs. Further, patients may be receiving controlled substances as an adjunct to interventional techniques, as well as to manage comorbid psychiatric and psychological disorders. Thus, the effectiveness studies published thus far may not apply in the majority of interventional pain management patients. Indeed, in an interventional pain practice, controlled substances may be prescribed at lower doses, particularly opioid analgesics, in conjunction with interventional techniques. It has also been shown that interventional techniques reduce psychological distress and improve functional status (307-330). More likely than not, the requirement for opioids and adjuvant drugs may be reduced or at least become stable. Hence, interventional pain physicians probably should not compare patients in their settings undergoing interventional techniques with others receiving drug therapy as mainstay. Monotherapy, particularly with opioids, may be appropriate for only a small subgroup of those with chronic pain.

The concept of “universal precautions,” first seen in medicine with the explosion of HIV and hepatitis tainted blood, was introduced to counter the misconception that a provider would be able to predict “by looking” who might have a communicable blood-borne disease. This led to the use of “precautions” (gloves, etc.) for all patients, regardless of their age or socioeconomic class. A rational approach to the treatment of chronic pain with opioids has been described using a pain and addiction continuum and a substance use assessment in a pain patient leading to the implementation of “universal precautions” in pain medicine (331).

8.2 Recommendation

Based on the grading recommendations provided by Guyatt et al (37) and illustrated in Table 2, the recommendation is 2A — weak recommendation, high-quality evidence: with benefits closely balanced with risks and burden; derived from RCTs without important limitations or overwhelming evidence from observational studies, with the implication that with a weak recommendation, best action may differ depending on circumstances or patients’ or societal values.

8.3 Basic Philosophy

Principles for prescribing opioids must require a comprehensive evaluation (mandatory physical and optional psychological), appropriate documentation at regular intervals to assess the efficacy of therapy, with specific evaluation of the impact on functional status, degree of pain relief, identification and treatment of undesirable side effects, and monitoring for abuse behaviors. In addition, there must be adherence to a controlled substance agreement and with
regulatory guidelines promulgated by various agencies. Fig. 6 shows an algorithmic approach to patient evaluation and management. Table 19 shows an algorithmic approach for chronic opioid therapy.

8.4 Evaluation

Appropriate history, physical examination, and medical decision-making based on the initial evaluation of a patient’s presenting symptoms are essential. The guidelines of the Centers for Medicare and Medicaid Services (CMS) provide various criteria for 5 levels of evaluation and management services (E&M) (332-335), with 3 crucial components: history, physical examination, and medical decision-making. Other components include counseling, coordination of care, nature of presenting problem, and time required for face-to-face evaluation. While there are numerous techniques to evaluate a chronic pain patient, which vary from physician to physician, institution to institution, and textbook to textbook, following the guidelines established by CMS will assist a physician in performing a comprehensive and complete evaluation complying with regulations.

Some of the aspects specific in controlled substance abuse and chronic pain include evaluation of the effect of pain on physical and psychological function, such as activities of daily living (336,337).

8.4.1 Diagnostic and Therapeutic Injections

Diagnostic interventional techniques will assist in making the proper diagnosis by following an algorithmic approach (338-345). It has been shown that in approximately 70% to 85% of the patients with spinal pain an accurate diagnosis may not be provided in spite of the available history, physical examination, EMG nerve conduction studies, and radiological evaluation. With precise diagnostic interventional
techniques, the chances of correct diagnosis may be improved substantially, and proper treatment may be offered (346-350).

Therapeutic interventional techniques also may be used in a monotherapeutic way rather than using opioids for pain management and functional improvement. The effectiveness of various interventional techniques has been evaluated in systematic reviews (307-330).

A written treatment plan should document objectives that will be used to evaluate treatment success, including pain relief and improved physical and psychosocial function, and should indicate if additional diagnostic tests, consultations, or treatments are planned. After starting treatment, the physician should adjust with care the drug therapy to the individual medical needs of each patient. In the continuum of treatment, other modalities, including interventional techniques, rehabilitation, and psychological therapy may be necessary depending on the etiology of the pain and the extent to which pain is associated with physical, functional, and psychosocial impairment.

**Table 19. Ten-step process: An algorithmic approach for long-term opioid therapy in chronic pain.**

<table>
<thead>
<tr>
<th>STEP</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Comprehensive initial evaluation</td>
</tr>
<tr>
<td>II</td>
<td>Establish diagnosis</td>
</tr>
<tr>
<td>III</td>
<td>Establish medical necessity (lack of progress or as supplemental therapy)</td>
</tr>
<tr>
<td>IV</td>
<td>Assess risk-benefit ratio</td>
</tr>
<tr>
<td>V</td>
<td>Establish treatment goals</td>
</tr>
<tr>
<td>VI</td>
<td>Obtain informed consent and agreement</td>
</tr>
<tr>
<td>VII</td>
<td>Initial dose adjustment phase (up to 8-12 weeks)</td>
</tr>
<tr>
<td>VIII</td>
<td>Stable phase (stable – moderate doses)</td>
</tr>
<tr>
<td>IX</td>
<td>Adherence monitoring</td>
</tr>
<tr>
<td>X</td>
<td>Outcomes</td>
</tr>
</tbody>
</table>

1. One prescribing doctor and one designated pharmacy.

2. Urine/serum drug screening when requested.
3. No early refills and no medications called in.
4. If medications are lost or stolen, then a police report could be required before considering additional prescriptions.
The reasons for which opioid drug therapy may be discontinued, such as violation of a documented doctor/patient agreement, should be delineated. Additional items to be included in an agreement are listed in Table 20.

Table 20. Sample Controlled Substance Agreement

We are committed to doing all we can to treat your chronic pain condition. In some cases, controlled substances are used as a therapeutic option in the management of chronic pain and related anxiety and depression, which is strictly regulated by both state and federal agencies. This agreement is a tool to protect both you and the physician by establishing guidelines, within the laws, for proper controlled substance use. The words “we” and “our” refer to the facility and the words “I”, “you”, “your”, “me”, or “my” refer to you, the patient.

1. i. I understand that chronic opioid therapy has been associated not only with addiction and abuse, but also multiple medical problems including the suppression of endocrine function resulting in low hormonal levels in men and women which may affect mood, stamina, sexual desire, and physical and sexual performance.

   ii. For female patients, if I plan to become pregnant or believe that I have become pregnant while taking this medication, I am aware that, should I carry the baby to delivery while taking these medications; the baby will be physically dependent upon opioids. I will immediately call my obstetrician and this office to inform them of my pregnancy. I am also aware that opioids may cause a birth defect, even though it is extremely rare.

   iii. I have been informed that long-term and/or high doses of pain medications may also cause increased levels of pain known as opioid induced hyperalgesia (pain medicine causing more pain) where simple touch will be predicted as pain and pain gradually increases in intensity and also the location with hurting all over the body. I understand that opioid-induced hyperalgesia is a normal, expected result of using these medicines for a long period of time. This is only treated with addition of non-steroidal anti-inflammatory drugs such as Advil, Ibuprofen, etc., or by reducing or stopping opioids.

   iv. I understand that physical dependence is not the same as addiction. I am aware physical dependence means that if my pain medicine use is markedly decreased, stopped, or reversed by some of the agents mentioned above, I will experience a withdrawal syndrome. This means I may have any or all of the following: runny nose, yawning, large pupils, goose bumps, abdominal pain and cramping, diarrhea, irritability, aches throughout my body and a flu-like feeling. I am aware that opioid withdrawal is uncomfortable, but not life threatening.

   v. I am aware that tolerance to analgesia means that I may require more medicine to get the same amount of pain relief. I am aware that tolerance to analgesia does not seem to be a big problem for most patients with chronic pain; however, it has been seen and may occur to me. If it occurs, increasing doses may not always help and may cause unacceptable side effects. Tolerance or failure to respond well to opioids may cause my doctor to choose another form of treatment, reduce the dose, or stop it.

2. i. All controlled substances must come from the physician whose signature appears below or during his/her absence, by the covering physician, unless specific authorization is obtained for an exception.

   ii. I understand that I must tell the physician whose signature appears below or during his/her absence, the covering physician, all drugs that I am taking, have purchased, or have obtained, even over-the-counter medications. Failure to do so may result in drug interactions or overdoses that could result in harm to me, including death.

   iii. I will not seek prescriptions for controlled substances from any other physician, health care provider, or dentist. I understand it is unlawful to be prescribed the same controlled medication by more than one physician at a time without each physician’s knowledge.

   iv. I also understand that it is unlawful to obtain or to attempt to obtain a prescription for a controlled substance by knowingly misrepresenting facts to a physician or his/her staff or knowingly withholding facts from a physician or his/her staff (including failure to inform the physician or his/her staff of all controlled substances that I have been prescribed).
### Table 20 (continued). Sample Controlled Substance Agreement

3. All controlled substances must be obtained at the same pharmacy where possible. Should the need arise to change pharmacies, our office must be informed. The pharmacy that you have selected is:

   ______________________________________________________
   Phone: _________________________________

4. i. You may not share, sell, or otherwise permit others, including your spouse or family members, to have access to any controlled substances that you have been prescribed.

   ii. Early refills will not be given. Renewals are based upon keeping scheduled appointments. Please do not make excessive phone calls for prescriptions or early refills and do not phone for refills after hours or on weekends.

5. Unannounced pill counts, random urine or serum, or planned drug screening may be requested from you and your cooperation is required. Presence of unauthorized substances in urine or serum toxicology screens may result in your discharge from the facility and its physicians and staff.

6. I will not consume excessive amounts of alcohol in conjunction with controlled substances. I will not use, purchase, or otherwise obtain any other legal drugs except as specifically authorized by the physician whose signature appears below or during his/her absence, by the covering physician, as set forth in Section 2 above. I will not use, purchase, or otherwise obtain any illegal drugs, including marijuana, cocaine, etc. I understand that driving while under the influence of any substance, including a prescribed controlled substance or any combination of substances (e.g., alcohol and prescription drugs), which impairs my driving ability, may result in DUI charges.

7. Medications or written prescriptions may not be replaced if they are lost, stolen, get wet, are destroyed, left on an airplane, etc. If your medication has been stolen, it will not be replaced unless explicit proof is provided with direct evidence from authorities. A report narrating what you told the authorities is not enough.

8. In the event you are arrested or incarcerated related to legal or illegal drugs (including alcohol), refills on controlled substances will not be given.

9. I understand that failure to adhere to these policies may result in cessation of therapy with controlled substances prescribed by this physician and other physicians at the facility and that law enforcement officials may be contacted.

10. I also understand that the prescribing physician has permission to discuss all diagnostic and treatment details, including medications, with dispensing pharmacists, other professionals who provide your health care, or appropriate drug and law enforcement agencies for the purpose of maintaining accountability.

11. I affirm that I have full right and power to sign and to be bound by this agreement, that I have read it, and understand and accept all of its terms. A copy of this document has been given to me.

   ______________________________________________________
   Patient’s full name

   ______________________________________________________  __________________________
   Patient’s signature      Date

   ______________________________________________________  __________________________
   Physician’s signature      Date
9.0 **Documentation and Medical Records**

The physician should keep accurate and complete medical records, which include all aspects of interventional pain management and medical care. These comprise, but are not limited to:

♦ The medical history and physical examination
♦ Diagnostic, therapeutic, and laboratory results
♦ Evaluations and consultations
♦ Treatment objectives
♦ Discussion of risks, benefits, and limitations of treatments
♦ Details of different treatments, medications, including date, type, dosage, and quantity prescribed
♦ Instructions to the patient
♦ Periodic reviews of outcomes, including documentation of functional status, preferably using validated tools

Records should remain current and be maintained in an accessible manner and readily available for review, not only for the physician and other members of the practice, but also for authorities.

To be in compliance with controlled substance laws and regulations required to prescribe, dispense, or administer controlled substances, the physician must have an active license in the state and comply with applicable federal and state regulations. Various boards have published regulations and recommendations for prescribing controlled substances. Physicians are advised to refer to those regulations for their respective state. Physicians should not prescribe scheduled drugs for themselves or immediate family except in emergency situations.

The following criteria should be considered carefully in providing controlled substances:

1. Complete initial evaluation, including history and physical examination
2. Psychological evaluation
3. Physiological and functional assessment, as necessary and feasible
4. Definition of indications and medical necessity:
   ♦ Pain of moderate-to-severe degree
   ♦ Suspected organic problem
   ♦ Documentation of failure to respond to non-controlled substances, adjuvant agents, physical therapy, and interventional techniques
   ♦ For patients with interventional techniques as primary modality, controlled substance drugs may be used as a second line treatment.
   ♦ For nonopioid controlled substances, appropriate documentation of psychological disorders should be maintained.
   ♦ Continued opioid prescription requires monitoring of “the 4 As”:
     • Analgesia
     • Activity
     • Aberrant behavior
     • Adverse effect

5. The use of the lowest possible dose to provide adequate analgesia with minimum side effects should be the goal of opioid therapy.
6. In general, do not combine opioids with sedative-hypnotics, benzodiazepines, or barbiturates for chronic, non-cancer pain unless there is a specific medical indication for the combination.
7. Adherence to the controlled substance agreement with patients understanding the risks and benefits of controlled substances and the policy and regulations of the practitioner, including controlled substances being prescribed by only one practitioner and being obtained from only one pharmacy.
8. Monitoring for drug abuse or diversion should be routine and if confirmed, referral to rehabilitation centers may be made, with termination of prescriptions of controlled substances.
9. Use caution when prescribing acetaminophen-containing opioids, especially given the ubiquitousness of acetaminophen in over-the-counter medications. Short-term use (< 10 days) should be less than 4,000 mg/day, while chronic use should probably be limited to 2,500 mg/day.

While there are no universally accepted tools to assess opioid responsiveness, it is important to use a tool that monitors both function and pain relief.

Although opioids may be useful for the treatment of chronic pain, aberrant behavior and/or no improvement in function and pain after an adequate trial of opioids should trigger a consideration to discontinue the opioids, tapered over a several week period to avoid withdrawal symptoms. Evidence of diversion or illegal use warrants an immediate discontinuation of the medication. Clonidine po or transdermal 0.1 mg can be offered to counteract the majority of withdrawal symptoms.
10.0 Key Points

1. These opioid guidelines for the treatment of chronic non-cancer pain were developed to improve the quality and appropriateness of care, improve patient access, improve patient quality of life, improve efficiency and effectiveness, and achieve cost containment by improving the cost-benefit ratio.
2. Opioids are extensively used in managing chronic pain.
3. There is significant evidence of opioid abuse in conjunction with or without illicit drugs.
4. Abuse terminology is variable. This document attempts to standardize and provide a common sense definition.
5. Opioid pharmacology is variable and essential to understand for proper management of patients.
6. Among the rules of opioid administration, comprehensive evaluation and diagnostic assessment is crucial, including diagnosis by interventional techniques.
7. Establishing goals of treatment and using a controlled substance agreement are essential in the practice of pain management with opioids.
8. Periodic review of the patient on opioids is essential, using appropriate adjustments, with routine assessment of analgesia, activity, aberrant behavior, and adverse effects.
9. Documentation, keeping accurate and complete medical records with all the essential elements to provide proper patient care and also meet regulatory and legal requirements, is essential.
10. The rationalization and importance of these guidelines lies in the fact that most available evidence documents a wide degree of variance in the prescribing patterns of opioids for chronic pain. The strength of available evidence in the use of opioids for chronic non-cancer pain is weak.

Acknowledgements

The authors wish to thank Leon McCallum, Department of Anesthesia, University of Florida, for his invaluable assistance in obtaining the articles for review and Tonie M. Hatton and Diane E. Neihoff, Transcriptionists; Vidyasagar Pampati, MSc, Statistician; Sekhar Edem, Research Assistant; Victoria Caldwell, Graphic Designer; and Ray Lane, Director of Education and Public Relations, for their assistance in the preparation of this manuscript.

Author Affiliations

Dr. Trescot is Director, Pain Fellowship, University of Florida, Gainesville, FL; and Director Malcolm Randall VA, Gainesville, FL

Dr. Helm II is with Pacific Coast Pain Management Center, Laguna Hills, CA

Dr. Hansen is Medical Director, The Pain Relief Centers, PA, Conover, NC

Dr. Benyamin is President and Medical Director, Millennium Pain Center, Bloomington, IL; and Clinical Assistant Professor, College of Medicine, University of Illinois, Urbana-Champaign, IL

Dr. Glaser is with Pain Specialists of Greater Chicago, IL

Dr. Adlaka, MD is with Pain Control Associates, Munster IN

Dr. Patel is a Pain Fellow, University of Florida, Malcolm Randall VA, Gainesville, FL

Dr. Manchikanti is Chief Executive Officer, ASIPP; Medical Director, Pain Management Center of Paducah, Paducah, KY; and Associate Clinical Professor, Anesthesiology and Perioperative Medicine, University of Louisville, Kentucky

Dr. Datta is Director, Vanderbilt University, Interventional Pain Program, and Associate Professor, Dept. of Anesthesiology, Vanderbilt University Medical Center, Nashville TN

Dr. Sehgal is Associate Professor of Rehabilitation Medicine, Medical Director of Interventional Pain Program, University of Wisconsin School of Medicine and Public Health, Dept. of Orthopedics and Rehabilitation, Madison, WI

Dr. Colson is Assistant Professor of Anesthesiology, Department of Anesthesiology, Pain Medicine Service, West Virginia University Hospitals, Morgantown, WV

Dr. Jordan is with Coastal Interventional Pain Associates, Myrtle Beach, SC

Dr. Lee, Jr. is Director of Pain Center at Affinity Health Group, Tifton, GA
REFERENCES


33. National Health and Medical Research Council (NHMRC). *How to Use the Evidence: Assessment and Application of Scientific Evidence*. NHMRC, Canberra,
Australia, 2000.

34. NHS Research and Development Centre of Evidence-Based Medicine. Levels of Evidence. http://cebm.jr2.ox.ac.uk


McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: Results from a nationally representative sample. Pain 2004; 111:77-83.


166. Monitoring the Future (MTF), National...


son G, Piraino PS, Eisenhower J, Har- 
sonyi Z, Darke AC. A randomized, dou-
ble-blind, 8-week crossover study of 
onece-daily controlled-release tramad-
ol versus immediate-release tramadol 
taken as needed for chronic noncancer 

303. Adams EH, Chwiecko P, Ace-Wagoner 
Y, Mangebrida B, Duermen ME, Perdi-
kis GC, Kunkel FA, Ghale R. A study of 
Avinza (morphine sulfate extended-re-
lease capsules) for chronic moderate-
to-severe noncancer pain conducted 
under real-world treatment conditions. 
- the ACPT study. Pain Pract 2006; 
6:254-264.

304. Rauck R, Ma T, Kerwin R, Ahdieh H. Ti-
tration with oxymorphone extended 
release to achieve effective long-term 
pain relief and improved tolerability in 
opioid-naive patients with moderate 
to severe pain. Pain Med 2007 (Published 
article online: 7-Dec-2007).

305. Cone J, Heit H, Caplan YH, Gourlay D. 
Evidence of morphine metabolism to 
hydromorphone in pain patients chron-
ically treated with morphine. J Anal Tox-
icol 2006;30:1-5.

306. Wasan A, Michna E, Janfaza D, Teter 
C, Greenfield S, Jamison R. Interpreting 
urine drug tests: prevalence of morphine 
metabolism to hydromorphone in chronic 

307. Boswell MV, Singh V, Staats PS, Hirsch 
JA. Accuracy of precision diagnostic 
blocks in the diagnosis of chronic spi-
nal pain of facet or zygapophyssial joint 
origin: A systematic review. Pain Phys-

308. Boswell MV, Colson JD, Spillane WF. 
Therapeutic facet joint interventions in 
chronic spinal pain: A systematic review of effectiveness and complica-

309. Boswell MV, Colson JD, Sehgal N, Dun-
bar EE, Epter R. A systematic review of 
therapeutic facet joint interventions in 
chronic spinal pain. Pain Physician 2007; 
10:229-254.

310. Sehgal N, Shah RV, McKenzie-Brown 
A, Everett CR. Diagnostic utility of fac-
et (zygapophyssial) joint injections in 
chronic spinal pain: A systema-
8:211-224.

311. Seghal N, Dunbar EE, Shah RV, Col-
son JD. Systematic review of diagnos-
tic utility of facet (zygapophyssial) joint 
injections in chronic spinal pain: An up-

312. Shah RV, Everett CR, McKenzie-Brown 
AM, Sehgal N. Discography as a diag-
nostic test for spinal pain: A systemat-
ic and narrative review. Pain Physician 

313. Abdi S, Datta S, Trescot AM, Schul-
tz DM, Adlaka R, Atluri SL, Smith HS, 
Manchikanti L. Epidural steroids in the 
management of chronic spinal pain: A 
systematic review. Pain Physician 2007; 
10:185-212.

314. Datta S, Everett CR, Trescot AM, Schultz 
HS, Shah RV. An updated systematic 
review of diagnostic utility of selec-
tive nerve root blocks. Pain Physician 

315. Trescot AM, Chopra P, Abdi S, Datta S, 
Schultz DM. Systematic review of ef-
fectiveness and complications of adhe-
siolysis in the management of chronic 
10:129-146.

316. Buenaventura RM, Shah RV, Patel V, Be-
nyamin R, Singh V. Systematic review 
of discography as a diagnostic test for 
10:147-164.

317. Hansen HC, McKenzie-Brown AM, Co-
hen SP, Swiecegood JR, Colson JD, Man-
chikanti L. Sacroiliac joint inter-
ventions: A systematic review. Pain Phys-

318. Bogduk N, Lord S. Cervical zygapophys-
ial joint pain. Neurosurg Q 1998; 
8:107-117.

N. False-positive rates of cervical zyg-
aphyssial joint blocks. Clin J Pain 

320. Barnsley L, Lord S, Bogduk N. Com-
parative local anesthetic blocks in the 
diagnosis of cervical zygapophysial 

321. Lord SM, Barnsley L, Bogduk N. The 
utility of comparative local anesthet-
ic blocks versus placebo-controlled 
blocks for the diagnosis of cervical zyg-
11:208-213.

322. Lord SM, Barnsley L, Wallis BJ, Bogduk 
N. Chronic cervical zygapophysial joint 
pain with whiplash: A placebo-con-
trolled prevalence study. Spine 1996; 
21:1737-1745.

323. Bogduk N. International spinal injec-
tion society guidelines for the perfor-
mance of spinal injection procedures. 

324. Bogduk N. Cervical medial branch 
blocks. In Practice Guidelines for Spi-
nal Diagnostic and Treatment Proce-
dures, 1st edition. International Spine 

325. Manchikanti L, Manchikanti KN, Man-
chukonda R, Pampati V, Cash KA. Evi-
uation of therapeutic thoracic medial 
branch block effectiveness in chronic 
 thoracic pain: A prospective outcome 
study with minimum 1-year follow up. 

326. Manchikanti L, Damron KS, Cash KA, 
Manchukonda R, Pampati V. Therapeu-
tic medial branch blocks in managing 
chronic neck pain: A preliminary report 
of a randomized, double-blind, con-
trolled trial: Clinical Trial NCT0033272. 

327. Manchikanti L, Pampati V, Fellows B, 
Bakhit CE. The diagnostic validity and 
therapeutic value of lumbar facet joint 
nerve blocks with or without adjuvant 

328. Manchikanti L, Rivera JJ, Pampati V, 
Damron KS, MCManus CD, Brandon 
DE, Wilson SR. One day lumbar epidu-
ral adhesiolysis and hypertonic saline 
nerveosis in treatment of chronic low 

329. Manchikanti L, Saini B, Singh V. Spi-
nal endoscopy and lysis of epidural ad-
sades in the management of chronic 
low back pain. Pain Physician 2003; 
4:240-265.

330. Manchikanti L, Pampati V, Fellows B, 
Rivera JJ, Beyer CD, Damron KS. Role of 
one day epidural adhesiolysis in man-
gagement of chronic low back pain: A 
randomized clinical trial. Pain Physi-
cian 2001; 4:153-166.

331. Gourlay DL, Heit HA, Almahrez A. Uni-
versal precautions in pain medicine: A 
rational approach to the treatment of 
112.

332. Manchikanti L. Recent developments in 
evaluation and management services. 

333. Manchikanti L. Evaluation and manage-
ment in interventional pain practice: 
Doing it right! Pain Physician 2000; 
3:322-341.

334. Manchikanti L. Role of evaluation and 
management services in pain manage-

335. Manchikanti L. Documentation for eval-
uation and management services. In 
Manchikanti L (ed). Interventional Pain 
Management: Principles and Practice


